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DEVELOPMENT OF LIPID-BASED NANO FORMULATIONS OF MIRIPLATIN
AGAINST LUNG CANCER

Abstract

By Zizhao Xu
University of the Pacific
2020

Cancer is the second leading cause of death and is responsible for approximately 9.6
million deaths worldwide in 2018. Among all oncological diseases, lung cancer claims the
highest mortality (male: 23.5%; female: 22%) and the second most new cases (male: 13%;
female: 12%) in the US. Approximately 40% of newly diagnosed lung cancer patients are in the
advanced stage IV, for which platinum-based chemotherapy is the first-line treatment, either by
itself or in combination with surgery or radiotherapy.
Cisplatin, the first-generation platinum-based anticancer chemotherapeutic agent, has the
highest potency against lung cancer but carries many severe adverse effects. Cisplatin also
induces drug resistance during long-term chemotherapy. Many more platinum complexes have
been investigated as better alternatives, which led to the approval of carboplatin and oxaliplatin
by Food and Drug Administration (FDA). In addition, miriplatin suspended in iodolipds
(lipiodolization) was approved in Japan for the treatment of hepatocellular carcinoma (HCC) in
2009. Miriplatin has the same non-leaving group as oxaliplatin but different leaving groups of
two myristate chains, which make it highly lipophilic.
Several characteristics of solid tumors in lung cancer constitute a physiochemical barrier
to the homogenous distribution and deep penetration of chemotherapy agents. Nanocarriers
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provide a promising platform to overcome the physiochemical barrier and to reduce the systemic
toxicity of anticancer chemotherapy. In this study, miriplatin is formulated with various lipidbased nanocarriers including micelles and solid lipid nanoparticles (SLNs) thanks to its highly
lipophilic structure. The goal of this thesis is to develop and evaluate miriplatin-loaded nano
formulations against lung cancer.
Miriplatin-loaded formulations were prepared by different methods, including thin film
hydration and several scale-up methods including chloroform dripping, chloroform injection,
chloroform evaporation, co-solvent evaporation, chloroform slow evaporation and co-solvent
slow evaporation. Between the two types of nano formulations under this study, micelles were
much smaller (~10 nm in diameter) and more homogeneous (PDI < 0.3), while SLNs were
bigger (~ 100 nm in diameter) and more heterogeneous (PDI ~0.8). A quantification method of
miriplatin was established using inductively coupled plasma-optical emission spectrometry (ICPOES). The quantification of platinum recovery from different miriplatin-loaded nano
formulations was facilitated by digestion with 70% nitric acid and heating. The co-solvent slow
evaporation method to prepare miriplatin-loaded nano formulations improved the platinum
recovery prominently from 10% to 70%. Thus, co-solvent slow evaporation has been established
as a pharmaceutically viable scale-up method to prepare nano formulations of miriplatin.
Miriplatin-loaded nano formulations of different compositions were negatively stained
with uranyl acetate and then imaged by transmission electron microscopy (TEM), which showed
the formulations’ size and morphology that were consistent with the size and PDI data from
dynamic light scattering studies by the Malvern Zetasizer. In the TEM studies, micelles showed
a morphology of spherical dots at around 10 nm in diameter while SLNs showed both spherical
and rod structures with a size distribution from 50 to 150 nm.
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A three-dimensional multicellular spheroid (3D MCS) model of A549-iRFP cells was
used for in vitro evaluation of the nano formulations’ activity against lung cancer. A549-iRFP
cells were engineered from the common lung cancer cell line A549 to stably express the nearinfrared fluorescent protein (iRFP). The viability of A549-iRFP 3D MCS after exposure to
cisplatin or nano formulations was similar to A549 3D MCS. The anticancer activity of
miriplatin-loaded nano formulations against 3D MCS was positively associated with the
platinum recovery as quantified by ICP-OES. The miriplatin-loaded nano formulations that had
been prepared by the co-solvent slow evaporation method showed substantial anticancer
activities against A549 3D MCS and A549-iRFP 3D MCS, which were comparable to cisplatin.
Taken together, miriplatin-loaded nano formulations were successfully prepared by cosolvent slow evaporation. The formulations were developed to carry favorable physiochemical
properties to enhance the activities of platinum drugs against lung cancer.
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CHAPTER 1: INTRODUCTION

1.1 Statement of the Problem
1.1.1 Lung Cancer
Cancer is a group of diseases which are characterized by the uncontrolled growth and
spread of abnormal cells [1]. Based on the latest updated data, cancer is the second leading
cause of death and is responsible for approximately 9.6 million deaths in 2018 [2]. More than
1.8 million new cancer cases are expected to be diagnosed and about 606,520 Americans are
expected to die from cancer in 2020 [1]. Among all oncological diseases, lung cancer claims the
highest mortality (male: 23.5%; female: 22%) and the second most new cases (male: 13%;
female: 12%) in the US [3]. Smoking tobacco is the leading cause of lung cancer but nonsmokers can also be diagnosed with lung cancer if they are exposed to other risk factors such as
radon, secondhand smoke, air pollution, asbestos and certain chemicals [4]. Personal and family
history of lung cancer is also a risk factor even for nonsmokers and light smokers.
Based on histological features, lung cancer can be classified into two types: non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most prevalent
type (85% of total cases) and has three main subtypes, namely adenocarcinoma, squamous cell
carcinoma and large-cell carcinoma (Figure 1.1) [5]. Adenocarcinoma represents about 60-70%
of NSCLC and tends to develop into solid tumors in peripheral bronchioles, which are usually
located more along the outer edges of the lungs. Squamous cell carcinoma comprises about 30%
of NSCLC and tends to arise in main bronchi and then advance to the carina [6]. Large-cell
carcinoma is more proximal in location and locally tends to develop tumors that lack the
common glandular or squamous morphology. SCLC is derived from the lung hormonal cells and
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accounts for the remaining 15% of lung cancer. It tends to develop intocentral mediastinal
tumors and disseminate aggressively into submucosal lymphatic vessels and nodes [5, 7].

Figure 1.1. Lung cancer classification. Adapted from [8].

1.1.2 Treatment Options and Chemotherapy
The treatment of lung cancer includes surgery, radiotherapy, chemotherapy, targeted
therapy and immunotherapy. The diagnosis of the histological subtypes and the stages of
progression are important for designing the treatment. Patients in stage Ⅰ, Ⅱ, and ⅢA are
typically suggested to have surgery to remove the tumor if the tumor is resectable and if the
patients can tolerate the surgery [9, 10]. Some patients may benefit from adjuvant therapy,
which includes radiation, chemotherapy, and targeted therapy, before or after the resection
surgery. If the tumor is too large, doctor may recommend using adjuvant therapy to shrink the
tumor size before surgery. Patients also receive chemotherapy after surgery to kill the remaining
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cancer cells and to reduce the risk of cancer relapse [11, 12]. Radiotherapy can help control or
eliminate tumors at specific sites using high-energy beams to damage DNA of cancer cells.
Radiotherapy also serves as part of palliative care to patients who do not respond to surgery or
chemotherapy [13]. Immunotherapy is a breakthrough treatment in oncology that uses people’s
own defense system to fight off cancer [14]. Generally, it can prevent cancer cells from
spreading to other regions of the body and can increase the effectiveness of the immune system
by targeting cancer cells to stop/slow their growth [15]. Immunotherapy treatments are typically
reserved for patients who have both local, advanced lung cancers and cancer cells have spread to
remote parts of the body. Targeted drug treatments focus on abnormalities that are specific to
the cancer cells and aim to block these abnormalities, such as epidermal growth factor receptor
(EGFR) mutations.
However, approximately 40% of newly diagnosed lung cancer patients are in stage IV
and the goal for treating these patients is to improve their survival time and to reduce diseaserelated adverse events [10]. Cytotoxic combination chemotherapy is the first-line therapy for
both advanced-stage NSCLC and advanced-stage SCLC [16, 17]. A platinum-based anticancer
drug (cisplatin or carboplatin) plus paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan, or
pemetrexed are usually given in a series of treatments over a period of weeks or months, with
breaks in between so that patients can recover [12, 18]. The specific combination depends on
different cancer types, performance status (PS), toxic effects and should be decided on an
individual basis [10]. Patients with performance status of 0, 1 or 2 are usually suggested to take
a platinum-based regimen, but patients with a PS of 3 do not benefit from cytotoxic
chemotherapy because of the high risk of adverse effects [10]. Therefore, a platinum-based
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combination chemotherapy plays a major role in lung cancer treatment, either by itself or in
combination with surgery or radiotherapy.
1.1.3 Platinum-Based Anticancer Drugs
The discovery of cisplatin and subsequent expansion of the platinum-based drug family
has revolutionized the treatment of lung cancer and other certain cancers. Platinum-based
chemotherapy drugs account for approximately 50% of clinically used anticancer therapeutic
agents [19]. Cisplatin was initially discovered as an antibacterial agent over 50 years ago and
later found to have potent anticancer effects over a wide range of cancers [20]. Cisplatin was
named by Dr. Rosenberg and approved by the US Food and Drug Administration (FDA) for
cancer treatment in 1978.
Cisplatin is administered to patients by intravenous infusion in saline solution either
individually or in combination with another therapeutic agent. The general mechanism of
cisplatin involves four steps (Figure 1.2): (1) cellular uptake, (2) aquation/activation, (3) DNA
binding, and (4) apoptosis [21, 22]. When administrated in bloodstream, cisplatin is relatively
stable and remains its initial chemical state due to the high concentration of chloride ion (~100
mM) [23]. It enters cells via passive diffusion or active transport by membrane transporters,
such as copper transporter proteins CTR1 [24]. Once inside cells, cisplatin undergoes
aquation/activation process, where the chlorine ligands of cisplatin are easily displaced by water
molecules due to the lower intracellular chloride concentration (~4-12 mM) [21, 25]. The
positively charged Pt-water complex ion is attracted to the negatively charged DNA, where it
binds to the nitrogen in the N7 position on purine bases (guanine and adenine) to form the crosslink adduct [26, 27]. The cells will then undergo apoptosis unless they promptly repair the
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damage. The cross-linking process is crucial to the cytotoxicity of cisplatin [28]. It is reported
that the number of the formation of Pt-DNA adduct can directly determine the cytotoxic effect
[19].

Figure 1.2. Cisplatin structure and its mechanism of action. Adapted from [19].

However, systemic administration of cisplatin also produces many severe adverse effects,
ranging from hearing loss to hemolysis [19]. Neurotoxicity is the major dose-limiting side
effect, which is a composite result of the transport of cisplatin into renal epithelial cells, injury to
DNA, activation of a multiple cell death and survival pathways and initiation of a robust
inflammatory response [29, 30]. Other common adverse effects including neurotoxicity and
ototoxicity are caused by the limited selectivity of cisplatin between normal cells and cancer
cells. Another major challenge of cisplatin is the rapid development of resistance. When
stressed with cisplatin, cancer cells can reduce the expression of the transporter that uptake
cisplatin (CTR1) and increase the production of glutathione to enhance DNA repair [31-33], both
contributing to drug resistance.
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To overcome the toxicity and the resistance of cisplatin, many more platinum complexes
have been investigated for their antitumor properties. The design of new platinum-based
anticancer agents involves strategic modification of several structural features (Figure 1.3) [34].
The non-leaving group ligands L of a platinum complex are typically nitrogen donors and form
thermodynamically stable bond with the platinum. Such non-leaving ligands usually maintain
unchanged during the drug activation and directly affect the nature of the final platinum-DNA
adduct [35, 36]. The leaving group ligands X, commonly halides and carboxylates, are labile
and can be replaced through ligand substitution. Modification of ligand X can change the
aquation/activation kinetics, toxicity profile and solubility [35, 36]. The axial ligands R are only
present in higher-valent platinum complexes, such as platinum (Ⅲ) and platinum (Ⅳ). These
ligands will ultimately dissociate after biological reduction but can be used for tumor-targeting
or for attachment to nanoparticles [34]. Any modification of these three types of ligands will
also change the platinum molecule’s lipophilicity and solubility, which are important
physicochemical parameters for drug design and drug delivery.

Figure 1.3. General structure of anticancer platinum agents. Adapted from [34].
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Although over a thousand platinum complexes have been synthesized and tested for
anticancer activity, only two platinum drugs are approved for clinical use worldwide and four
additional compounds approved for regional use in Asia [21, 37].

Figure 1.4. The family tree of platinum anticancer agents. Copyright from [22].

Carboplatin was approved by FDA in 1989 as a second-generation Platinum-based drug
[37, 38]. It contains the same non-leaving group as cisplatin but a different leaving group,
chelating 1,1-cyclobutanedicarboxylate (CBDCA), which leads to a lower toxicity profile.
Although carboplatin can be administered at a higher dosage than cisplatin, it exhibits crossresistance with cisplatin because they share the same non-leaving group [39, 40]. Oxaliplatin
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gained FDA approval for treatment of colon cancer in 2002 as a third generation of platinumbased anticancer drug [37, 38]. Oxaliplatin has another chelating ligand (oxalate) as the leaving
group and a different non-leaving group,1R,2R-diaminocyclohexane (DACH), which exhibits a
different spectrum of anticancer activity [41]. Because of the different non-leaving group,
oxaliplatin usually showed no cross-resistance with cisplatin. Further, oxaliplatin needs to be
activated by replacing the oxalate ligand with chloride ion [42]. It has been reported that
oxaliplatin is more dependent on organic cation transporters (overexpressed in colon cancer) than
copper transporters for uptake by cancer cells [24, 43]. Oxaliplatin is the first clinically
approved platinum drug that can overcome cisplatin resistance. In addition, nedaplatin,
heptaplatin and lobaplatin have been approved in Japan, South Korea and China, respectively, as
alternatives of cisplatin [37, 38].
Miriplatin was approved in Japan for lipiodolization in the treatment of hepatocellular
carcinoma (HCC) in 2009. It has the same non-leaving group as oxaliplatin and two myristate
chains as leaving groups, which makes miriplatin a highly lipophilic complex. In clinic, it is
administered into the hepatic artery using an oily lymphographic agent, Lipiodol Ultra-Fluide®
as a carrier to release the active platinum compounds into the aqueous phase gradually, which is
similar to the transformation of oxaliplatin. Miriplatin can be considered as a fourth generation
of platinum drug to improve delivery and reduce toxicity, especially in liver [44].
1.1.4 Barriers of Drug Delivery into Solid Tumor
The limitations of anticancer chemotherapy have been primarily ascribed to drug toxicity
and drug resistance at the cellular level. However, substantial evidence suggests that tumor
microenvironment (TME) also mediates resistance of solid tumors against chemotherapy [45].
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As in many solid tumors, the TME of NSCLC exhibits many distinctive physiological
characteristics (Figure 1.5) which are different from normal tissue, including vascular structure,
interstitial pressure, and multiple gradients of cell proliferation, nutrients, oxygen and therapeutic
agents [46, 47]. In normal tissues, drug molecules with low molecular weight can enter the
vascular network and readily perfuse the tissues due to the concentration gradient[48]. By
contrast, the distribution of many anticancer drugs is heterogeneous in solid tumors. The
insufficient penetration prevents a high proportion of the tumor cells from exposure to
potentially lethal concentration of the anticancer drug, especially deep in the core of the solid
tumors.

Figure 1.5. Physiological Characteristics of Tumor Tissue and Vasculatures. Adapted from [48].
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Solid tumors can be seen as heterogeneous organ-like structural complex consisting of
cancer cells and stromal cells [45]. Compared with normal tissues, the tumor stroma contains an
altered extracellular matrix and an increased number of fibroblasts that synthesize growth
factors, chemokines, and adhesion molecules [45, 49]. The tumor stroma, which varies greatly
among tumors, can influence malignant transformation, cancer invasion and metastasis, and the
sensitivity to drug treatment [50-52]. In addition, a tumor’s response to chemotherapy is also
influenced by its abnormal vasculature and blood flow. Unlike normal tissue, tumor
microvasculature shows disorganization and lack of the conventional hierarchy of blood vessels,
which interferes with the homogeneous distribution of anticancer drugs within tumor [53, 54].
For an example, the leaky blood vessels in solid tumor allow macromolecules to reach tumor
cells but also cause high interstitial pressures, which inhibits the drug accumulation [55].
Furthermore, the lack of functional intratumoral lymphatic vessels inhibits the clearance of
extracellular fluid, further contributing to interstitial hypertension within tumors [56]. These
structural abnormalities of tumor blood vessels are the main reason of the heterogeneity of blood
supply and cell proliferation within the tumor microenvironment.
In summary, several characteristics of solid tumors in lung cancer constitute a
physiochemical barrier to the homogenous distribution and deep penetration of chemotherapy
agents.
1.2 Strategies for Effective Drug Delivery to Solid Tumors
Nanotechnology provides a promising platform to overcome the aforementioned
physiochemical barrier against intratumoral drug distribution and to reduce the systemic toxicity
of anticancer chemotherapy. Generally, nanocarriers are colloidal drug carrier systems with size
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usually less than 500 nm in diameter. They are used for encapsulation and delivery of
hydrophilic and/or hydrophobic drug molecule(s) to improve their bioavailability and therapeutic
efficacy. Compared with chemotherapeutic agents with low molecular weight, nano drug
delivery systems can help to improve solubility, stability, pharmacokinetic profile, drug release,
and drug targeting [57].
1.2.1 Passive Targeting
Passive targeting, also known as physical targeting, can enhance the accumulation of
therapeutic agent at the target site by catering the physicochemical properties of the drug
delivery system to the distinctive characteristics of the pathologic tissue [47]. The enhanced
permeation and retention (EPR) effect, which was proposed as an innovative strategy to deliver
macromolecular drugs in 1986, is one mechanism of passive targeting [58]. The enhanced
permeation of nanocarriers or macromolecules at the tumor site is caused by tumor vascular
leakage while the enhanced retention is due to the impaired lymphatic drainage within neoplastic
tissues [59]. Compared to tightly aligned normal vasculature with 10 nm or smaller fenestrae,
the blood vessels inside solid tumors contain large fenestrae ranging from 100 to 700 nm in
diameter, which enables selective extravasation of nanocarriers into the tumor interstitium [57].
The leaky tumor vasculature also allows excessive fluid extravasation, which generates high
interstitial pressure and non-functional lymphatic drainage, which in turn enhances the retention
of nanocarriers inside solid tumors [48, 60]. Hence, the increased vascular permeability and
poor lymphatic drainage results in the selective accumulation and retention of nanocarriers in
tumor tissues.
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The cut-off size for the extravasation varies, but 200 nm in diameter or below is generally
accepted for the solid tumor vasculature [61]. In order to achieve a sufficient accumulation of
nanocarriers at tumor site, polyethylene glycol (PEG) is usually used to modify the surface of
nanocarriers to extend their time of circulation in blood. The hydrophilic PEG polymer can
hinder the adsorption of serum proteins (opsonization) and thus hinder their recognition and
clearance by the reticuloendothelial system (RES) [62]. Therefore, when administered
intravenously, PEG-coated nano delivery systems tend to circulate for longer time if they are not
small enough (40 kDa) to be excreted by renal filtration or large enough to be recognized by the
RES [48, 63].
Although the EPR effect is thought to significantly benefit nanocarriers, including
Doxil®, Caelyx® and Abraxane® [48], which are now in clinical use, there are several
challenges in this mechanism of passive targeting for anticancer drug delivery. Compared to
normal organs, the EPR effect may provide only modest tumor specificity of 20–30% increase in
drug delivery [48, 64]. In addition, the benefit of the EPR effect varies by tumor types and
depends on the following factors: (1) the degree of angiogenesis and lymphangiogenesis; (2) the
degree of perivascular tumor growth and the density of the stromal response; and (3) intratumor
pressure [48]. Together with the physicochemical characteristics of nanocarriers, all these
factors will affect the drug delivery efficiency. Some researchers also proposed three methods
that might improve the EFP effect: (1) modulating tumor blood flow; (2) modulating the tumor
vasculature and stroma; and (3) killing cancer cells to reduce the barrier function of solid tumors
[48, 65].
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1.2.2 Active Targeting
Active targeting is strategies of grafting or tagging nanocarriers with targeting ligands,
which can specifically bind to over-expressed receptors on the surface of tumor cells. Compared
to passive targeting, active targeting can help deliver more drug molecules into targeted cells by
receptor-mediated endocytosis instead of interstitial accumulation [64]. The strong and highly
selective interaction between the ligand and receptor can decrease non-specific binding and
toxicity in normal tissues. It has been reported that the involvement of receptor-mediated
endocytosis can also suppress multidrug resistance because it circumvents drug efflux by Pglycoprotein [66]. The first proof of concept for the strategy of active targeting was published in
1980 in a report on liposomes grafted with antibodies [67]. A numbers of receptors have been
found to be overexpressed in cancer cells, followed by investigations on their binding ligands for
active targeting, including proteins, peptides, polysaccharides, aptamers and small molecules
[64, 68-70]. For example, it has been found that RGD peptide binds to αVβ3 integrin, which are
highly presented on both the glioma cells and vasculature of TME [71].
1.2.3 Lipid-Based Nanocarriers
Nano drug carriers can be classified into organic and inorganic nanoparticles. Compared
with inorganic nanoparticles, such as mesoporous silica nanoparticles and gold nanoparticles,
organic nanoparticles are more commonly used due to their better biocompatibility.
Phospholipids are the major component of the cell membrane, so they commonly serve as
biocompatible and biodegradable key components organic nanoparticles for drug delivery.
Approximately 40% of lipophilic drug candidates fail due to poor water solubility or formulation
stability issues. Lipid-based nanoparticles can help formulate those molecules and help deliver
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and release them at the target site of action to lower both acute and chronic toxicity [72, 73].
Based on the lipid composition and the nano-sized structure, lipid-based nanoparticles mainly
include micelles, liposomes, solid lipid nanoparticles (SLNs) (Figure 1.6).

Figure 1.6. Examples of lipid-based nanoparticles: micelles, liposomes and solid lipid
nanoparticles (SLNs). Adapted from [74].

Additionally, the physiochemical properties of lipid-based nanocarriers can be catered to
the unique characteristics of solid tumors in order to increase the efficiency of drug targeting and
delivery [73]. Based on the cut-off size for renal excretion and tumor permeation as mentioned
before, a size range between 10 to 100 nm would be optimal for drug targeting and delivery.
Neutral or negatively charged surface of nanocarriers is preferred to prolong circulation time and
reduce renal clearance [75]. It is well known that a spherical shape promotes cellular interaction
and cellular uptake [76]. However, it has also been reported that rod-shaped structures might be
internalized more efficiently than spherical structures [77, 78]. Furthermore, nanocarriers are
commonly modified with the hydrophilic polymer PEG to reduce opsonization and thus to
prolong circulation [79].
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1.2.3.1 Micelles. Micelles are spherical colloids consisting of a core of nonpolar groups
of its surfactant monomers and a surface of polar groups of the same surfactant monomers.
Depending on the structure of the monomers, the size of the micelle varies from 10 nm to 100200 nm [80]. For an example, micelles made of lipid-PEG conjugates usually have a size of no
more than 20 nm in diameter [81, 82]. The extremely small size of micelles might be beneficial
to the tumor penetration and accumulation. Compared to other nanoparticles, micelles usually
form at higher concentration of the monomers, which is known as critical micelle concentration
(CMC). The usually high CMC value of micelles might lead to their insufficient stability in vivo.
1.2.3.2 Liposomes. Liposomes are the most commonly used nanocarriers and represent
the majority of FDA-approved nanomedicines for cancer therapy. Liposomes are mainly
composed of phospholipids and has the structure of a shell of lipid bilayer enclosing an aqueous
interior, which allows the loading of both lipophilic and hydrophilic drug molecules [83, 84].
Hydrophilic molecules can be encapsulated in the aqueous core while lipophilic molecules can
be incorporated into the lipid bilayer. Compared to micelles, liposomes have a larger size
ranging from 50 to 500 nm. The size and surface charge of a liposome preparation depend on
both the lipid composition and the preparation method. Liposomes can be modified by PEG
polymer and targeting ligands on the surface in order to prolong circulation time and to increase
tumor accumulation. The in vivo stability and the drug loading for hydrophilic drugs of
liposomes are still challenging. It was reported that the encapsulation of hydrophobic drugs
inside the aqueous core destabilized the lipid bilayer structure resulting in drug leakage and
colloidal instability [85]. In order to overcome the instability caused by opsonization,
tremendous researches focused on modifying liposomes with hydrophilic molecules such as PEG
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or monosialoganglioside to generate “stealth liposomes” that can evade the recognition and
clearance by RES [86, 87].
1.2.3.3 Solid lipid nanoparticles (SLNs). SLNs are nanocarriers containing a
hydrophobic core of solidified lipid molecules. SLNs carry a size ranging from 50 to 1000 nm in
diameter [74, 88]. SLNs have the flexibility of size and surface modification. The major
components of SLNs are solid lipids such as triglycerides, free fatty acids, fatty acid alcohols,
waxes and steroids, which are all used for dispersion and entrapment of hydrophobic drugs. The
solidification/crystallization of the lipids sometimes results in particles with non-spherical shape
[74]. The solid lipid molecules are solid at room and body temperatures, which means that SLNs
have much better stability than micelles and liposomes. Besides the excellent physically
stability, SLNs also have the advantages of sustained drug release, high drug loading capacity
and biodegradability [89].
1.3 Miriplatin-Loaded Nano Formulations and their Proposed Mechanism of Action
Due to the highly lipophilic structure and compatibility with phospholipid and solid lipid
molecules, miriplatin can be formulated into various lipid-based nanocarriers. The appropriate
physiochemical properties will allow nanocarriers to passively target to lung solid tumors. After
they reach cancer cells, miriplatin will enter cancer cells either by endocytosis together with
nanocarriers or by diffusion by itself. The myristate chains of miriplatin will be replaced by
chloride ions to transform miriplatin into smaller, active platinum-containing compounds,
followed by further activation by water molecules and crosslinking with DNA to kill cancer
cells.
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Figure 1.7. Proposed mechanism of action of miriplatin-loaded nano formulations--passive
targeting of miriplatin-loaded nano formulation to lung solid tumor.

Figure 1.8. Proposed mechanism of action of miriplatin-loaded nano formulations--cellular
uptake of miriplatin-loaded nano formulation in lung solid tumor cells.
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1.4 Hypothesis and Specific Aims
Based on the foregoing, we hypothesize that lipid-based nano formulations of miriplatin
would carry appropriate physiochemical properties to improve the anticancer activity of platinum
drugs against lung cancer. To test the hypothesis, the research of this thesis is focused on the
following specific aims:
1. To develop a methodology to construct miriplatin-loaded nano formulations;
2. To characterize the physiochemical properties and the morphology of miriplatinloaded nano formulations;
3. To evaluate the anticancer activity of miriplatin-loaded formulations against threedimensional multicellular spheroids (3D MCS).
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CHAPTER 2: PREPARATION OF MIRIPLATIN-LOADED NANO FORMULATIONS

2.1 Introduction
2.1.1 Strategies to Prepare Nano Formulations
It is widely known that lipid-based nanoparticles are mainly composed of natural or
synthetic lipids. Due to the lipid molecules’ amphiphilic property, they tend to form aggregation
like nanoparticles or microparticles when they are exposed to aqueous phase in order to
minimize the exposure of their hydrophobic moieties to water molecules [90].
Numerous techniques have been developed to prepare lipid-based nano formulations,
such as thin film hydration method, ethanol injection method, solvent evaporation method,
microfluidic technique, and high pressure/hot homogenization technique. The main challenges
are to control the energy input during the preparation of nanoparticles and to apply appropriate
lipid-to-drug and organic phase-to-aqueous phase ratios [91, 92].
In research labs, some preparation methods such as thin film hydration are easily
executed but can only prepare nano formulations in small scale. Generally, lipids and
hydrophobic drugs are dissolved into a volatile organic solvent or mixture of organic solvents
[93]. After evaporating the organic solvent(s) under reduced pressure to form a thin film,
aqueous buffer is added at temperature above the lipid transition temperature followed by freethawing and membrane extrusion. It is difficult for human eyes to assess the quality of the thin
film, such as homogeneity and thickness, so the batch-to-batch reproducibility can be a huge
challenge.
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In industry, solvent injection is the most commonly used way to prepare nano
formulations. Generally, lipids dissolved in organic solvent(s) (eg. ethanol) is injected into
aqueous phase slowly at a temperature above the transition temperature of the lipids. The size of
the lipid-based formulations prepared by this technique can be controlled by adjusting the speed
of injection, which determines the ratio of organic phase/aqueous phase during the mixing. The
outcome of solvent injection can also be explained by two crucial speeds [94] – the speed at
which the lipids and hydrophobic cargo drug molecules precipitate from the organic phase and
the speed at which they form particle in aqueous phase. Application of appropriate injection
speed to control these two speeds can facilitate the preparation of nanoparticles with optimal size
and can reduce material loss during the preparation. The solvent evaporation method can be seen
as a modified solvent injection method, in which the water-immiscible organic solvent is
emulsified in aqueous phase by injection, but by stirring at high speed [93]. The two crucial
speeds of lipid/cargo precipitation and formation of particles are controlled by the evaporation of
organic solvent. The residual organic solvent need to be removed completely, otherwise it will
damage biomolecules and tissues once the formulations are administrated to patients [93].
Other commonly used methods such as microfluidic technique and spray-drying method
share similar mechanism to the two methods mentioned previously but need more specialized
instruments [92, 93, 95].
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Figure 2.1. Schematic representation of formation of lipid-based nanoparticles by solvent
injection method [94].

2.1.2 Components of Miriplatin-Loaded Formulations
Miriplatin is a highly lipophilic platinum anticancer drug containing myristates (C-14
fatty acid) as leaving groups and diaminocyclohexane (DACH) as a carrier ligand [96]. The two
C-14 chains greatly influence the solubility of miriplatin and make it similar to the structure of
lipids, especially phospholipids. In this way, miriplatin can not only be considered as an
anticancer drug but also a lipidic component inside our formulations.
It is well acknowledged that combination therapy (IV infusion with two anticancer drugs
together or sequentially) can achieve significantly better anticancer efficacy and lower toxicity in
clinic cancer treatment [97]. In this study, paclitaxel (PTX) will be used as a secondary
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anticancer drug inside the lipid nano formulations because the chemotherapy regimens with
platinum-based drugs (cisplatin or carboplatin) and paclitaxel are first-line treatments for nonsmall cell lung cancer. Paclitaxel, another hydrophobic drug molecule, can be easily formulated
into the lipophilic core of lipid-based nano formulations such as micelles and solid lipid
nanoparticles [82, 98, 99].
Trimyristin (TM) and tripalmitin (TP) are triglycerides synthesized by formal acylation
of the three hydroxy groups of glycerol by myristic (tetradecanoic) acid and palmitic
(hexadecanoic) acid, respectively. Both TM and TP have already been widely utilized as major
components of solid lipid nanoparticles [99, 100]. Paclitaxel-loaded SLN of tripalmitin have
also been successfully prepared and studied by some researchers [99]. TM and TP have similar
length of carbon chains to miriplatin so we expect that they both would be easily compatible with
miriplatin to form lipid nanoparticles.
18:0 PE-PEG2000 is a commonly used pegylated lipid in nano formulations to prolong
circulation time, increase stability and reduce opsonization. In addition, because it is an
amphiphilic polymeric molecule, it can form spherical colloidal nanoparticles such as micelles
by self-assembly [82, 98].
In this study, various miriplatin-loaded formulations such as micelles and SLNs have
been prepared and characterized by size and polydispersity index (PDI). Miriplatin-loaded
micelles were prepared with 18:0 PE-PEG2000 only, while miriplatin-loaded SLNs were prepared
with triglycerides (TM or TP) and 18:0 PE-PEG2000. Miriplatin or miriplatin/paclitaxel are used
as anticancer payload drug(s) of the nano formulations. In addition, several scale-up preparation
methods (including solvent injection and solvent evaporation) for miriplatin-loaded nano
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formulations were investigated. Due to the poor solubility of miriplatin in most organic solvents,
chloroform was chosen as the major component of the organic phase to dissolve miriplatin. The
preparation methods will be discussed one by one in this chapter and summarized in a table at
the end of Chapter 3.

Figure 2.2. Schematic structures of miriplatin-loaded micelles (left) and miriplatin-loaded SLNs
(right).

2.2 Materials and Methods
2.2.1 Materials
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] ammonium salt (18:0 PEG2000 PE) was purchased from Avanti Polar Lipids, Inc.
(Alabaster, AL, USA). Miriplatin was purchased from MedChemExpress LLC (NJ, USA).
Cholesterol, Glycerol trimyristate, Glycerol tripalmitate were purchased from Sigma-Aldrich. 2[4-(2-hydroxyethyl) piperazin-1-yl]-ethanesulfonic acid (HEPES) was purchased from Fisher
Scientific. All other organic solvent and chemicals were purchased from Sigma Aldrich, Fisher
Scientific or VWR.
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2.2.2 Preparation Methods for Miriplatin-Loaded Formulations
2.2.2.1 Preparation of miriplatin-loaded formulations by film hydration. A solution
of 4 µmol various lipids and additional 0.8 µmol miriplatin in chloroform was mixed in glass
tube. The residual organic solvent was removed by rota-vaporation and further drying under
high vacuum overnight. The lipid film was then hydrated with HEPES buffer (5 mM, pH 7.4)
containing 150 mM NaCl. The tube was filled with argon, sealed with parafilm and then put into
a 75 °C water bath for at least 30 min. Mild sonication and vortexing were applied to facilitate
hydration to obtain a micelle or SLN formulation of miriplatin.
2.2.2.2 Preparation of miriplatin-loaded formulations by chloroform dripping. A
solution of various lipids and miriplatin in chloroform was prepared in a larger scale (at least 5
times: 20 µmol total lipids and 4 µmol miriplatin) in glass tube. The hydration buffer, HEPES
buffer (5 mM, pH 7.4) containing 150 mM NaCl, was preheated and equilibrated in a 75 °C
water bath on a stirring hot plate (Fisher Scientific). The chloroform solution was pre-warmed
and added dropwise into the above-mentioned aqueous phase of HEPES buffer. The two phases
were kept stirring at 75 °C for 30 min until all chloroform was evaporated. Further mild
sonication and vortexing were applied to facilitate hydration and homogeneity to obtain a
micellar or SLN formulation of miriplatin.
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Figure 2.3. Schematic illustration of the chloroform dripping method.

2.2.2.3 Preparation of miriplatin-loaded formulations by chloroform injection. A
solution of various lipids and miriplatin in chloroform was prepared in a larger scale as described
above. The hydration buffer, HEPES buffer (5 mM, pH 7.4) containing 150 mM NaCl, was
preheated and equilibrated in a 75 °C water bath on a stirring hot plate. The chloroform solution
of miriplatin and lipids was pre-warmed and injected into aqueous phase slowly. The mixture
was kept stirring at 75 °C for 30 min until all chloroform was evaporated. The resultant aqueous
colloidal solution was sonicated and vortexed mildly to enhance hydration and sample
homogeneity to obtain a micellar or SLN formulation of miriplatin.
2.2.2.4 Preparation of miriplatin-loaded formulations by chloroform evaporation. A
solution of various lipids and miriplatin in chloroform was prepared in a larger scale as described
above. The aqueous phase, HEPES buffer (5 mM, pH 7.4) containing 150 mM NaCl, was put
into a water bath on a stirring hot plate at room temperature. The chloroform solution as the
organic phase (2 to 3 mL) was added into the aqueous phase under constant mixing by a stirring

44
bar. The temperature of the mixture was increased from room temperature to 75 °C and then
kept at 75 °C for 30 min until all chloroform was evaporated. Further mild sonication and
vortexing were applied to facilitate hydration and the dispersion to yield the miriplatin-loaded
micellar or SLN formulation.
2.2.2.5 Preparation of miriplatin-loaded formulations by co-solvent evaporation. A
solution of various lipids and miriplatin was dissolved in a co-solvent (chloroform/iso-propanol
mixed in different ratio) in a larger scale as described above. The hydration buffer, (5 mM
HEPES, 150 mM NaCl, pH 7.4) was put into a flask in water bath on a stirring hot plate at room
temperature. The co-solvent solution of lipids and miriplatin (2 to 3 mL in total) was added into
the hydration buffer under constant mixing. The temperature was then increased from room
temperature to 85 °C. The mixture was kept stirring at 85 °C for an additional 30 min until all
organic solvents were evaporated. Further mild sonication and vortexing were applied to the
resultant aqueous suspension to facilitate hydration and dispersion in order to obtain a miriplatinloaded micellar or SLN formulation.
2.2.2.6 Preparation of miriplatin-loaded formulations by slow chloroform
evaporation. A solution of various lipids and miriplatin in chloroform was prepared in a larger
scale as described above. The hydration buffer (5 mM HEPES buffer, 150 mM NaCl, pH 7.4)
was put into a flask in water bath on a stirring hot plate at room temperature. The chloroform
solution (2 to 3 mL) was added into the hydration phase and mixed well by constant stirring.
The temperature of the mixture was then slowly increased from room temperature to 75 °C
(approximately ten centigrade every 30 min from room temperature until 60 °C, and then five
centigrade every 30 min until 75 °C). The mixture was stirred at 75 °C for another 30 min until
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all chloroform was evaporated. Further mild sonication and vortexing were applied to facilitate
hydration and dispersion to obtain a miriplatin-loaded micellar or SLN formulation.
2.2.2.7 Preparation of miriplatin-loaded formulations by co-solvent slow
evaporation. A solution of various lipids and miriplatin in co-solvent (chloroform/iso-propanol
mixed in different ratios) was prepared as described above. The hydration buffer (5 mM
HEPES, 150 mM NaCl, pH 7.4) was put into a flask in water bath on a stirring hot plate at room
temperature. The co-solvent solution (2 to 3 mL in total) was added into the hydration buffer
and mixed well by constant stirring. The temperature was slowly increased from room
temperature to 85 °C (approximately ten centigrade every 30 min from room temperature until
60 °C, and then five centigrade every 30 min until 85 °C). The mixture was stirred at 85 °C for
another 30 min until all organic solvents were evaporated. Further mild sonication and vortexing
were applied to facilitate hydration and dispersion to obtain a miriplatin-loaded micellar or SLN
formulation.

Figure 2.4. Schematic of co-solvent slow evaporation method.
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2.2.2.8 Preparation of selected miriplatin-loaded lipid nano formulations by cosolvent slow evaporation. Selected miriplatin-loaded formulations, whose compositions are
shown in Table 2.1., were prepared by co-solvent slow evaporation method as described in
2.2.2.7.

Table 2.1
Composition of Selected Miriplatin-Loaded Lipid Nano Formulations
Nanocarriers Lipid composition
Drug input (%)
micelles

SLNs

100% PE-PEG2000

20% miriplatin

100% PE-PEG2000

20% miriplatin+10% PTX

90% TM/10% PE-PEG2000

20% miriplatin

90% TP/10% PE-PEG2000

20% miriplatin

90% TM/10% PE-PEG2000

20% miriplatin+10% PTX

90% TP/10% PE-PEG2000

20% miriplatin+10% PTX

80% TM/10% Chol/10% PE-PEG2000

20% miriplatin

80% TP/10% Chol/10% PE-PEG2000

20% miriplatin

(TM: trimyristin, TP: tripalmitin, PE-PEG2000: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (ammonium salt), Chol:
cholesterol, PTX: paclitaxel)

2.2.3 Physicochemical Characterizations of Miriplatin-Loaded Nano Formulations
The sizes and Polydispersity Index (PDI) of the miriplatin-loaded formulations were
measured by dynamic light scattering using Zetasizer ZS 90 (Malvern Instruments Ltd., Malvern,
UK). An aliquot (3 µL) of miriplatin-loaded formulations diluted with deionized water (150 µL)
was transferred into a low volume cuvette (ZEN0118, Malvern Instruments) and the
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hydrodynamic diameter was measured in triplicates. The size distribution based on intensity,
volume and number was analyzed by Zetasizer software.
2.3 Results and Discussion
Miriplatin-loaded formulations consisting of miriplatin, solid lipids (trimyristin or
tripalmitin) and 18:0 PE-PEG2000 were successfully prepared by different procedures and
characterized by dynamic light scattering to measure their size and PDI. Miriplatin was
compatible with solids lipids and pegylated lipid to form lipid-based formulations due to their
similar structures.
2.3.1 Size Distribution of Miriplatin-Loaded Formulations Based on Intensity, Volume and
Number Weighing from the Malvern Zetasizer Software
Dynamic Light Scattering (DLS) is a well-established technique to measure the size of
nanoparticles [101]. DLS monitors the change of intensity of scattered light from nanoparticles
in suspension as they move in and out of the orifice of the detector due to Brownian motion. The
recorded data are then converted into size and a size distribution using the Stokes-Einstein
relationship. The weighing of the size distribution can be presented based on the intensity of the
light scattered by the nanoparticles, the volume of the nanoparticles, and the number of the
nanoparticles. In this study, the size and the size-distribution are reported based on the number
of the nanoparticles, although intensity-based distribution is also commonly used for
nanoparticles. Intensity-based distributions weigh more on species that have the largest
scattering intensity while number-based distributions stress more on species with the highest
number of particles, which tend to be smaller particles. For this reason, investigations of small
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nanoparticles (usually around or smaller than 100 nm in diameter) more commonly use numberbased distribution to present the DLS data rather than intensity-based distribution [82, 98].

Figure 2.5. An example of intensity-based size distribution of miriplatin-loaded SLN from
Malvern Zetasizer software.

Figure 2.6. An example of volume-based size distribution of miriplatin-loaded SLN from
Malvern Zetasizer software.
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Figure 2.7. An example of number-based size distribution of miriplatin-loaded SLN from
Malvern Zetasizer software.

As shown in Fig 2.5-2.7, nano formulations with multiple peaks in size distribution and a
large PDI (e.g., miriplatin-loaded SLNs), was poorly represented by the intensity-based
calculation of size distribution. However, the number-based size distribution could represent the
size of the majority of the nanoparticles, which also could be reflected by TEM images in
Chapter 3. By contrast, as shown in Picture 2.8-2.10, miriplatin-loaded micelles of good
homogeneity had similar size results whether the data is presented based on intensity or size.
Hence, all the sizes of miriplatin-loaded nano formulations in this study are represented in
number-based distribution.
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Figure 2.8. An example of intensity-based size distribution of miriplatin-loaded micelle from
Malvern Zetasizer software.

Figure 2.9. An example of volume-based size distribution of miriplatin-loaded micelle from
Malvern Zetasizer software.
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Figure 2.10. An example of number-based size distribution of miriplatin-loaded micelle from
Malvern Zetasizer software.

2.3.2 Effect of the Payload Drug Miriplatin to the Nano Formulations
SLNs with or without the payload miriplatin were prepared by chloroform dripping and
their sizes and PDI values are listed in Table 2.2. As shown in Table 2.2, the size and PDI of the
SLN formulations with miriplatin were smaller than those without miriplatin. The PDI values of
SLN formulations with or without miriplatin were all below 0.3, which indicates good
homogeneity.
Because of its unique chemical structure with two C14 hydrocarbon chains, miriplatin
can be considered as both the anticancer payload drug and a lipid component inside the
formulations. Therefore, appropriate amount of miriplatin would be well compacted with other
lipids (TM, TP and PE-PEG2000) to form denser colloids of smaller size and PDI.
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Table 2.2
Composition, Size and PDI of SLNs with or without Miriplatin
SLNs Compositions
Drug input (%)
Size (number, nm)

PDI

95% TM/5% PE-PEG2000

/

148.1

0.303

95% TP/5% PE-PEG2000

/

148.5

0.202

95% TM/5% PE-PEG2000

20% miriplatin

121.2

0.254

95% TP/5% PE-PEG2000

20% miriplatin

107.4

0.186

(TM: trimyristin, TP: tripalmitin, PE-PEG2000: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N- [methoxy (polyethylene glycol)-2000] (ammonium salt))

2.3.3 Effect of Lipid Components
The effect of lipid components (TM, TP and pegylated lipid) on the size and PDI of their
miriplatin nano formulations is evaluated using selected lipid compositions. The SLN and
micelle formulations of different compositions were prepared by chloroform dripping and their
size and PDI measured by dynamic light scattering (Table 2.3 and Table 2.4). The sizes of the
SLN formulations ranged from 30 nm to 120 nm and most of their PDI were around or below
0.3. For the same ratio of triglyceride lipid/PE-PEG2000, most sizes of SLNs consisting of the
triglyceride lipid TP were slightly smaller than the SLNs consisting of the other triglyceride lipid
TM. Additionally, in SLNs of the same triglyceride lipid (TM or TP) the higher the mole
percentage of PE-PEG2000 the lower the size would be. Micelles, which could also be considered
as 100% PE-PEG2000 + 0% solid lipids, can be fit into this trend as well, so the size of miriplatinloaded formulations could change from 10 nm to 120 nm as the percentage of PE-PEG2000
changes from 100% to 5%.
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Table 2.3
Size and PDI of Miriplatin-Loaded Formulations (SLNs and Micelles) with Different Lipid
Compositions
SLNs Compositions
Drug input (%)
Size (number, nm)
PDI
95% TM/5% PE-PEG2000

20% miriplatin

126.6

0.237

95% TP/5% PE-PEG2000

20% miriplatin

104.1

0.382

90% TM/10% PE-PEG2000

20% miriplatin

81.81

0.255

90% TP/10% PE-PEG2000

20% miriplatin

47.72

0.460

85% TM/15% PE-PEG2000

20% miriplatin

63.05

0.491

85% TP/15% PE-PEG2000

20% miriplatin

105.6

0.490

80% TM/20% PE-PEG2000

20% miriplatin

38.36

0.263

80% TP/20% PE-PEG2000

20% miriplatin

23.59

0.587

100% PE-PEG2000

20% miriplatin

12.52

0.391

(TM: trimyristin, TP: tripalmitin, PE-PEG2000: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N- [methoxy (polyethylene glycol)-2000] (ammonium salt))

It is well acknowledged that the size of nano drug delivery systems has a significant
impact on their tissue distribution and stability in blood circulation [102]. It is reported that
nanocarriers with a size lower than 150 nm in diameter can escape from the fenestrated
capillaries of solid tumors to penetrate into the tumor interstitium (aka enhanced permeation and
retention effect, EPR effect) and 200 nm is the cut off size to cause such EPR effect for passive
targeting[65, 103]. Moreover, the openings of blood vessels in normal tissues are less than 10
nm so nano drug delivery systems larger than 10 nm would get across the openings of the tumor
blood vessels easily but not those of normal blood vessels to cause adverse effect [91]. The sizes
of FDA approved nano formulations, such as Doxil® (pegylated liposomal doxorubicin) and
Abraxane® (albumin-bound paclitaxel), are all in the range of 50-150 nm [91, 104, 105].
Therefore, our miriplatin-loaded formulations ranging 30-120 nm in diameter may serve as valid
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nanocarriers of anticancer drugs. The SLNs (90% TM/TP + 10% PE- PEG2000 + 20% Miripatin)
with a diameter around 50-80 nm and micelles (100% PE-PEG2000 + 20% Miripatin) with a
diameter around 10 nm are chosen for further studies.
2.3.4 Comparison of Different Methods to Prepare Nano Formulations
Miriplatin-loaded SLNs consisting of the same lipid composition (90% TM/TP + 10%
PE- PEG2000 + 20% miripatin) were successfully prepared by different procedures and
characterized. Their composition, size and PDI were compared in Table 2.5.
2.3.4.1 Thin film hydration method vs. scale-up preparation methods. Compared to
other SLNs prepared by scale-up methods, SLNs prepared by thin film hydration method had
similar sizes but much better PDI values indicating better homogeneity of nano formulation,
which was caused by the good quality of the thin film and the well-established methodology by
previous lab mates. However, one critical step of thin film hydration, which is organic solvents
evaporation by rota-vaporator needed to be practiced several times in order to form a uniform
thin film and the resultant SLNs may still have batch-to-batch variance. The scale of thin film
hydration could be no more than several hundred microliters while other preparation methods
could achieve at least one-milliliter scale. Therefore, thin film hydration method would be
suitable for small scale experiments to try different compositions for the sake of saving cost,
while scale-up methods would be more practical for further industrial production.
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Table 2.4
Size and PDI of Miriplatin-Loaded SLNs (90% TM/TP + 10% PE-PEG2000 + 20% Miriplatin)
Prepared by Different Preparation Procedures
SLN compositions
Preparation methods
Size (number, nm) PDI
+ drug input (%)
90% TM /10% PEG +20% Miri

Thin film hydration

86.68

0.261

90% TP/10% PEG +20% Miri

Thin film hydration

91.45

0.241

90% TM /10% PEG +20% Miri

Chloroform dripping

59.83

0.252

90% TP/10% PEG +20% Miri

Chloroform dripping

49.92

0.397

90% TM /10% PEG +20% Miri

Chloroform injection

100.1

0.363

90% TP/10% PEG +20% Miri

Chloroform injection

98.10

0.613

90% TM /10% PEG +20% Miri

Chloroform evaporation

82.62

0.634

90% TP/10% PEG +20% Miri

Chloroform evaporation

277.0

0.623

90% TM /10% PEG +20% Miri

Co-solvent evaporation

466.7

0.552

90% TP/10% PEG +20% Miri

Co-solvent evaporation

381.7

0.385

90% TM /10% PEG +20% Miri

Chloroform slow evaporation

70.15

1.000

90% TP/10% PEG +20% Miri

Chloroform slow evaporation

85.74

0.582

90% TM /10% PEG +20% Miri

Co-solvent slow evaporation

95.92

0.800

90% TP/10% PEG +20% Miri

Co-solvent slow evaporation

132.5

0.394

(TM: trimyristin, TP: tripalmitin, Miri: miriplatin, PEG: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt))

2.3.4.2 Solvent evaporation methods. Compared to chloroform dripping method,
solvent evaporation methods yielded slightly larger formulations around 100 nm. This might be
caused by higher encapsulation efficiency of miriplatin inside formulations (90% TP/10% PEG
+20% miriplatin), which will be discussed in detail in the next chapter.
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The sizes of SLN formulations prepared by the co-solvent evaporation method were
much larger than SLNs prepared by other solvent evaporation methods. Because chloroform is
immiscible with water and miriplatin is insoluble in water, the transition of miriplatin between
the organic phase and the aqueous phase may be too low for efficient drug loading. Therefore, a
co-solvent, was added to improve the miscibility of the organic phase and the aqueous phase. As
shown in Table 2.6, although a number of solvents are miscible with both chloroform and water,
isopropanol (IPA) was attempted as the co-solvent because it had better solubility of miriplatin
than other co-solvents. The size of SLNs could be controlled by changing the percentage of IPA
and the speed of the solvent evaporation. From the observed precipitation during or after the
preparation procedures, slow evaporation did help lipids and miriplatin precipitate out of organic
solvents gradually and slowly and them formed nanoparticles in aqueous phase, which also could
be reflected by the drug recovery of nano formulations in Chapter 3. The boiling point of IPA is
83 °C so the final temperature of preparation was kept at 85 °C to drive its evaporation to
completion. The long duration and high temperature of the preparation procedure may cause the
degradation of miriplatin in aqueous buffer, which could be addressed in future studies by
evaporating the organic solvents under reduced pressure.
The PDI values of SLNs prepared by co-solvent evaporation were much higher than 0.3,
which might be caused by lower solubility of miriplatin in water and precipitation from the
system. For future studies, the SLNs can be filtered to remove large particles and thus to further
improve their homogeneity.
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Figure 2.11. Solvent miscibility table [106].

Table 2.5
Solubility of Miriplatin/Solid Lipids (TM/TP) in Co-Solvents
Secondary organic solvent
Chloroform
percentage (%)

percentage (%)

Ethanol

Acetone

Isopropanol

100

0

√

√

√

75

25

√

√

√

50

50

√

×

√

25

75

×

×

√

0

100

×

×

×
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2.3.5 Size and Polydispersity Index (PDI) of Miriplatin-Loaded Formulations Prepared by
Co-Solvent Slow Evaporation
Miriplatin-loaded SLNs and Micelles of selected compositions were successfully
prepared by co-solvent slow evaporation. Such formulations’ composition, size and PDI are
shown in Table 2.7 and Table 2.8.

Table 2.6
Composition, Size and PDI of Selected SLN Formulations Prepared by Co-Solvent Slow
Evaporation Method
SLNs Compositions
Drug input (%)
Size (number, nm)

PDI

90% TM/10% PE-PEG

20% miriplatin

109.2

0.801

90% TP/10% PE-PEG

20% miriplatin

143.6

0.948

90% TM/10% PE-PEG

20% miriplatin + 10% PTX

138.1

0.872

90% TP/10% PE-PEG

20% miriplatin + 10% PTX

82.08

1.000

80% TM/10% Chol/10% PE-PEG 20% miriplatin

142.1

0.667

80% TP/10% Chol /10% PE-PEG

83.32

0.911

20% miriplatin

(TM: trimyristin, TP: tripalmitin, PE-PEG2000: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N- [methoxy (polyethylene glycol)-2000] (ammonium salt), Chol:
cholesterol, PTX: paclitaxel)

Table 2.7
Composition, Size and PDI of Selected Micelle Formulations Prepared by Co-Solvent Slow
Evaporation Method
Micelles Compositions
Drug input (%)
Size (number, nm)
PDI
100% PE-PEG2000

20% miriplatin

11.90

0.247

100% PE-PEG2000

20% miriplatin + 10% PTX

11.71

0.254

(TM: trimyristin, TP: tripalmitin, PE-PEG2000: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N- [methoxy (polyethylene glycol)-2000] (ammonium salt), PTX:
paclitaxel)
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2.3.5.1 Comparison of different nanocarriers. In Table 2.7, there was not too much
difference in size and PDI between miriplatin-loaded SLNs of different compositions. The sizes
were all in the range of 80-150 nm and the PDI were all around 0.8, indicating poor
homogeneity. The slight difference in size might be caused by the poor controlling of the
temperature increasement. As discussed earlier, the speed of solvent evaporation would
influence the speed of lipid/miriplatin precipitation and nanoparticle formation. The manual
increase of temperature might not be controlled as precisely as instrument, so this problem could
be solved by computer programming to achieve precise thermal control.
Compared to SLNs, the variance in the size and PDI of miriplatin-loaded micelles were
negligible. The micelles had much smaller size around 10 nm and PDI lower than 0.3,
suggesting that the micelle delivery system with PE-PEG2000 as the major lipid component was
compatible with miriplatin. The C18 long chains of PE-PEG2000 further suggest that triglycerides
with longer chains such as tristearin might also be a compatible lipid component of the SLN
formulations of miriplatin. The small size of the micelles might enhance their penetration into
solid tumors but might also generate stability and pharmacokinetics problems in vivo.
Miriplatin-loaded liposome formulations consisting of phospholipid, cholesterol and
pegylated lipid were prepared, too. However, such formulations showed inferior
physicochemical and biological properties in our preliminary studies and hence were not
subjected to further studies.
2.3.5.2 Effect of cholesterol. It was reported that cholesterol can affect the fluidity of
bilayer structure and occupy the cavities between fatty acid chains to inhibit the movement of
hydrocarbon chains [107]. Therefore, cholesterol is widely used as a stabilizer in lipid-based
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formulations [108]. However, in our studies, adding cholesterol did not improve or worsen the
homogeneity or stability of miriplatin-loaded SLNs (Table 2.7). This is probably because the
core of the SLNs under our study is already filled with hydrocarbon chains of either the lipids or
miriplatin so that cholesterol might not be able to permeate and stabilize the SLNs as usual.
However, cholesteryl palmitate and cholesteryl myristate may be alternatives of cholesterol to
further stabilize miriplatin formulations.
2.4 Summary
Miriplatin-loaded formulations were successfully prepared by different preparation
methods, including thin film hydration method and several scale-up methods (chloroform
dripping, chloroform injection, chloroform evaporation, co-solvent evaporation, chloroform slow
evaporation and co-solvent slow evaporation). In the future, this method could be further
optimized to reduce batch-to-batch variance and to improve homogeneity. Different
compositions of the nano formulations have been investigated. Higher percentage of the
pegylated lipid PE-PEG2000 in the composition can result in a smaller size. Among the two types
of nano formulations under this study, micelles were much smaller (~ 10 nm in diameter) and
more homogeneous (PDI < 0.3), while SLNs were bigger (~ 100 nm in diameter) and had a more
heterogeneous size distribution that would need improvement (PDI ~0.8).
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CHAPTER 3: PHYSICOCHEMICAL CHARACTERIZATION OF MIRIPLATIN-LOADED
NANO FORMULATIONS

3.1 Introduction
3.1.1 Solubility of Miriplatin
Miriplatin was approved in Japan for the treatment of hepatocellular carcinoma (HCC) in
2009. It can be easily suspended in ethyl esters of iodized fatty acids obtained from poppy seed
oil and keeps its dispersed state for a long duration [44]. In clinic, it is administered into the
hepatic artery as a suspension in an oily lymphographic agent (Lipiodol Ultra-Fluide®) to
gradually release the active platinum compounds [44, 96]. The miriplatin/Lipiodol suspension is
exclusively used for HCC in Japan and is the only formulation of miriplatin in clinical use. The
narrow application and the limited pharmaceutical development are mainly due to its extremely
low solubility in water (<0.00260 mg/mL) [109]. Among organic solvents commonly used in
research labs (such as methanol, ethanol, acetonitrile and acetone), miriplatin can be only well
dissolved in chloroform above 1 mg/mL.
3.1.2 Quantification of Miriplatin
Inductively coupled plasma mass spectrometry (ICP-MS) uses inductively coupled
plasma to atomize the sample and produce excited atoms and ions, which are then detected by
their emitted electromagnetic radiation at wavelengths characteristic of a particular element. The
plasma is applied by a high temperature source of ionized source gas (often argon). In this way,
ICP-MS can specifically trace an element of interest regardless of its form, which makes it a
highly attractive method to detect trace level of elements in biological fluids [110]. Heavy
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metals, such as platinum, gold and palladium can all be quantified by ICP-MS, even those in
water-insoluble molecules. The last decade sees a slow shift towards ICP-MS from other older
techniques of detection such as atomic emission and atomic absorption [110]. ICP-MS offers
plenty of attractive features including high sensitivity, wide elemental coverage, multi-element
capability, and simple sample preparation [110].
Additionally, inductively coupled plasma optical emission spectrometry (ICP-OES), is an
alternative analytical technique used for the detection of chemical elements. Compared to ICPMS, ICP-OES enjoys simpler method development and lower cost but has higher limit of
detection. Both ICP-MS and ICP-OES have been widely applied in the analysis of metal
elements in pharmaceutical formulations [111, 112].

Figure 3.1. Diagram of a typical ICP-OES instrument with radial configuration of the detection
system [113].
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In this study, a method to quantify miriplatin was established by ICP-OES. In order to
quantify the platinum drugs inside miriplatin-loaded nano formulations at high recovery, which
is the percentage of the detected platinum by the total input platinum, several agents (nitric acid,
sulfuric acid and aqua regia) were used to digest nano formulations before injection into ICPOES. Moreover, Xia’s group have published a quantification method for miriplatin and
miriplatin-loaded liposomes by high performance liquid chromatography (HPLC) [109]. Thus,
another HPLC method of quantifying miriplatin in the nano formulations under this study was
attempted.
3.1.3 Transmission Electron Microscopy (TEM)
In nanotechnology, TEM serves as an essential tool for characterizing the morphology
and particle size of nano drug carriers [114]. The principle of transmission electron microscopy
(TEM) is to image a sample by detecting electrons after they transmit through the sample [115].
An ultrathin section of the specimen was formed on a grid followed by applying an accelerated
beam of electrons and generating an image with the transmitted electrons. Metals would scatter
electrons to appear darker against the background. By contrast, non-metals that cannot scatter
electrons need additional staining techniques to visualize [115]. Positive staining is used to
visualize samples’ inner components (such as organelles inside cells) while negative staining can
help to visualize the structure and size [116].
In this study, the miriplatin-loaded nano formulations were negatively stained with uranyl
acetate, then observed and imaged under TEM. The morphology of nanocarriers with different
compositions was compared and the sizes were compared with size data generated from dynamic
light scattering.

64
3.2 Materials and Methods
3.2.1 Materials
Miriplatin was purchased from MedChemExpress LLC (NJ, USA). Two-hundred mesh
continuous carbon-coated copper grids were obtained from TED PELLA (Redding, CA). All
other organic solvent and chemicals were purchased from Sigma Aldrich, Fisher Scientific or
VWR.
3.2.2 Quantification of Miriplatin by HPLC
Quantification of miriplatin was performed with high performance liquid
chromatography (HPLC) equipped with Waters 2695 separations module coupled to 2996
photodiode array detector. The stationary phase (Agilent ZORBAX SB-C8, 3.5 µm; 4.6 × 150
mm) was kept at 30 ℃, and the mobile phase (methanol: water: acetonitrile = 92:7.5:0.5, v/v)
was run at the flow rate of 1 mL/min. Effluent was monitored at wavelength 210 and 220 nm.
In order to enhance the dissolution of miriplatin in methanol, gentle heating and sonication were
applied to achieve a maximum concentration of 500 µg/mL. The calibration curve of miriplatin
was established using standard solutions of miriplatin (10, 20, 50, 100, 200, 250, 500 µg/ml) that
were diluted from a stock solution at 500 µg/ml. An aliquot (10 µL) of each standard solution
was injected into HPLC 0, 4, 8, 12, 24 hours after preparation.
3.2.3 Mass Spectrometer
MS spectra were recorded using a Varian 320 ESI-MS spectrometer at the Chemistry
Department. The mass spectrometer was used for quality control (QC) samples containing
miriplatin and operated in positive ion mode. The drying gas temperature was 160 °C and the
capillary voltage was 5000 V. Miriplatin was dissolved in methanol (5-50 µg/mL) before
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injection into the MS spectrometer. Analysis of the QC samples was performed 3 times after the
blank runs.
3.2.4 Quantification of Miriplatin by ICP-OES
Quantification of miriplatin by inductively coupled plasma-optical emission spectrometry
(ICP-OES) was performed at the Chemistry Department. The serial platinum standard solutions
for the calibration curve (5, 10, 50, 100, 1000, 10 000 ng/mL) were prepared by dilution from a 1
g/mL platinum standard solution (Inorganic Ventures, VA, USA) and were measured on a
Thermal Fisher iCAP 6000 series instrument at wavelengths 214.4 and 265.9 nm . The
calibration curves of cisplatin and miriplatin were established with the same serial platinum
standard solutions in 5% nitric acid. Each sample was measured in triplicates.
3.2.5 Quantification of Recovery of Platinum in Miriplatin-Loaded Nano Formulations by
ICP-OES
In order to determine the recovery of platinum quantification for miriplatin-loaded nano
formulations, different agents were used to digest nano formulations, including nitric acid,
sulfuric acid and aqua regia. Heating with nitric acid for 90 min was chosen as the general
digestion method to release platinum from the nano formulations into aqueous phase for
quantification. Specifically, an aliquot (50 µL) of formulations was taken and diluted into 3.45
mL 70% concentrated nitric acid followed by heating at 90 ℃ for at least 90 min. After cooling
down, an aliquot (500 µL) of the digestion solution was diluted into 6.5 mL deionized water to
achieve the lower concentration of nitric acid (5%) that is suitable for the injection into ICPOES. Each sample was measured in triplicates. The concentration of platinum in the miriplatinloaded nano formulations was estimated by the calibration curve of platinum standard solutions
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as mentioned in 3.2.4. The recovery of platinum from miriplatin-loaded nano formulations is
calculated by the following formula:
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%)
=

𝑃𝑙𝑎𝑡𝑖𝑛𝑢𝑚 𝑎𝑚𝑜𝑢𝑛𝑡 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑓𝑟𝑜𝑚 𝐼𝐶𝑃
× 100%
𝑃𝑙𝑎𝑡𝑖𝑛𝑢𝑚 𝑎𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑑𝑑𝑒𝑑 𝑚𝑖𝑟𝑖𝑝𝑙𝑎𝑡𝑖𝑛 𝑑𝑢𝑟𝑖𝑛𝑔 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔

3.2.6 Characterization of Miriplatin-Loaded Nano Formulations by TEM
The morphology of miriplatin-loaded nano formulations was studied on a JEOL-JEM
1230 Electron Microscope (JEOL, Japan). Two-hundred mesh carbon-coated copper TEM grids
were exposed to glow discharge to increase hydrophilicity before usage. An aliquot (5 µL) of
nano formulation was deposited on a grid and air-dried for at least 60 seconds. Excess liquid on
the grid was blotted with filter paper to generate a thin film, which was then quickly stained with
2% uranyl acetate and blotted with filter paper for cycles. The grid was then transferred into the
transmission electron microscope for imaging with the help of Dr. Fei Guo from Electron
Imaging Facility, Department of Molecular and Cellular Biology at UC Davis. The digital
images of the nano formulations from TEM were recorded and analyzed with EMMENU4
(TIETZ imaging software).
3.3 Results and Discussion
3.3.1 Quantification of Miriplatin by HPLC
3.3.1.1 Calibration curve of miriplatin by HPLC. The elution peaks of miriplatin was
monitored by ultraviolet spectrophotometer at wavelengths 210, 220, 254 and 280 nm, and the
maximum wavelength of miriplatin was found at 210 nm. Figure 3.2 displayed the
chromatogram of free miriplatin at a series of concentrations in methanol (10, 20, 50, 100, 200,
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250, 500 µg/ml). Due to the limited solubility in methanol, miriplatin standards gave both
increasing retention time (from 7.5 min to 8.5 min) and broader elution peaks as the
concentration increases. Addition of acetonitrile to decrease the mobile phase polarity sharpened
the elution peaks. However, because miriplatin has an even lower solubility in acetonitrile than
methanol, acetonitrile could not be added at a higher percentage to improve the shape of the
elution peaks.

Figure 3.2. Chromatograms of free miriplatin (10, 20, 50, 100, 200, 250, 500 µg/ml) by HPLC.

The calibration curves of miriplatin at wavelength 210 nm and 220 nm (Figure 3.3) both
showed an R square value above 0.999 in linear regression, indicating that the concentration of
miriplatin had a linearly relationship with the area under the peak in HPLC chromatogram over
the concentration range from 10 to 500 µg/mL.
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Figure 3.3. Calibration curve of miriplatin UV absorbance at wavelengths 210 and 220 nm in
HPLC.

3.3.1.2 Calibration curve of miriplatin by HPLC (AUC decreased along with time).
As shown in Figure 3.4, AUC (area under curve) from HPLC chromatogram decreased by
percentage as time went by, from the 0 h to 24 hours after the first injection. This might be
caused by miriplatin’s extremely low solubility in water (<0.00260 mg/mL) [109] and relatively
low solubility in methanol. Although about 0.5 mg/mL miriplatin could be dissolved in
methanol after mild sonication and heating, miriplatin might precipitate back out of the solution
after some time of storage at room temperature.

69

AUC (uV*sec)

2000000

0h
4h

1500000

8h
12 h

1000000

24 h
500000
0
0

100

200

300

400

500

600

Miriplatin Concentrations （ ug/mL）

Figure 3.4. The change of AUC in calibration curve of miriplatin over time.

It is well documented that platinum-based drugs are not stable in aqueous media because
the leaving groups of the platinum complex will be replaced by hydroxy groups [19, 42]. The
miriplatin molecules may not be stable in methanol as well in that the two myristate leaving
groups of miriplatin could be replaced gradually by molecules in the mobile phase such as water
and methanol. In our studies, the gradually decreasing AUC of the miriplatin standards indicate
that miriplatin may not be precisely quantified by HPLC due to its low solubility and stability in
water and methanol, even though the calibration curves from HPLC were in good linearity after
the preparation of the platinum standards. Therefore, the quantification method by HPLC was
not applied further to quantify miriplatin in its nano formulations.
3.3.2 Mass Spectrometry of Miriplatin
ESI-MS: chemical formula: C34H68N2O4Pt, m/z value of the most abundant isotope peak
of [M’+H]+: calculated 764.490518, found 764.8. Chemical Formula: C20H41N2O2Pt, [M”]+:
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calculated 536.281588, found 536.1; [M”+H2O]+: calculated 554.292153, found 554.1;
[M”+CH3OH]+: calculated 568.307803, found 568.3.

Figure 3.5. ESI-MS mass spectrum of miriplatin.

From the ESI-MS mass spectrum in Figure 3.5, we found that the strongest peak
corresponds to miriplatin molecules that have lost one myristate chain. But this could be
explained by the prior findings that miriplatin was not stable in methanol and existed as a
molecule losing one chain. Miriplatin was not easily ionized so the temperature and voltage
setting of its ESI-MS needed to be increased, which would enhance its degradation. However,
this phenomenon indirectly supports our hypothetical mechanism of the anticancer activities of
miriplatin-loaded nano formulations, in which miriplatin would degrade into myristate chains
and other platinum-containing fragments, which would then be released from the nano
formulation to kill the surrounding cancer cells.
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3.3.3 Quantification of Miriplatin by ICP-OES
3.3.3.1 Calibration curve of platinum standard solutions by ICP-OES. As shown in
Figure 3.6, the calibration curves of platinum standard solutions measured at wavelengths 214.4
and 265.9 nm were established by ICP-OES. Both of them had high R square (0.9999)
indicating that the concentration of platinum had a linear relationship with ICP-OES signals over
the concentration range from 10 ng/mL to 100 µg/mL. We found the ICP-OES signals at 10
ng/mL or lower platinum concentrations no longer fit to the calibration curves very well,
indicating that the limit of detection (LOD) of the instrument was around 10 ng/mL platinum.
This LOD of ICP-OES is critical for the quantification of platinum-based drugs, especially in
animal studies, whose samples will contain highly diluted platinum in blood. Due to the LOD
and high volume for ICP-OES measurements (around 6 mL for each sample), further biological
studies of platinum nano formulations in vitro and in vivo need to be designed carefully to ensure

Detection Concentrations
from ICP (ng/mL)

enough volume and concentration for each sample.
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Figure 3.6. Calibration curves of platinum standard solutions at wavelength 214.4 and 265.9 nm
by ICP-OES.
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3.3.3.2 Calibration curves of different forms of platinum. It is well known that ICP
only trace the element no matter what form it is. As shown in Figure 3.7, different forms of
platinum including platinum standard solution, cisplatin and miriplatin at the same platinum
concentrations showed great consistency with each other. Thus, the measurement would reflect
the concentration of miriplatin (or other platinum-based drugs such as cisplatin and oxaliplatin)
and its degradation products. The limit of detection of the three forms of platinum was all

Pt Measurments from ICP

around 10 ng/mL, which was consistent with the result mentioned in 3.3.3.1.
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Figure 3.7. Calibration curves of different forms of platinum (platinum standard solution,
cisplatin, miriplatin) at wavelength 214.4 nm by ICP-OES.

3.3.4 Recovery in the Quantification of Platinum from Miriplatin-Loaded Nano
Formulations by ICP-OES
Different digestion methods (nitric acid, sulfuric acid and aqua regia) have been tried to
optimize the recovery in quantifying the platinum from miriplatin-loaded nano formulations by
ICP-OES in preliminary studies. Although some manuals suggested using aqua regia for the
digestion of formulations consisting of platinum [117, 118], this digestion method was
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abandoned in later study because it was far more dangerous than the others and needed high
diluted of the digested sample before its injection into the ICP-OES instrument. Nitric acid and
sulfuric acid showed similar recoveries of platinum from nano formulations. Based on our
preliminary data and on the usage experiences of Dr. Zhao’s lab, heating in 70 % nitric acid at
90 ℃ for 90 min was chosen to digest nano formulations in further experiments.
3.3.4.1 Comparison of platinum recovery from different miriplatin-loaded nano
formulations. The composition and platinum recovery of miriplatin-loaded SLNs prepared by
different procedures were shown in Table 3.1. All nano formulations were digested by 70%
nitric acid at 90 ℃ for 90 min.
The two initial scale-up methods to prepare miriplatin-loaded nano formulations, namely
chloroform dripping method and chloroform injection method gave the lowest platinum
recoveries, which was probably due to the loss of miriplatin during the dripping/injection
procedure. When chloroform solution touched the hot aqueous phase (75 ℃), chloroform would
evaporate very quickly to precipitate out lots of lipids and the payload miriplatin due to their low
solubility in water. This quick precipitation would then prevent miriplatin from assembling with
the lipids to yield a high loading or high recovery of platinum.
The solvent evaporation method with or without co-solvent and the slow evaporation
method improved the platinum recovery significantly (from 10% to 20-30%). It is probably
because the slow evaporation gave the two phases (organic phase and aqueous phase) more time
to mix well and gave the lipids and miriplatin more time to form nanoparticles together in
aqueous phase slowly. Adding co-solvent and slow evaporation were two positive contributors
to platinum recovery but they did not show prominent improvement individually. Co-solvent
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could help lipids transfer from organic phase to aqueous phase gradually and smoothly because
of the better miscibility while slow evaporation could let two phases have more time to mix and
transfer. Furthermore, the platinum recovery improved drastically from 20% to 80% when both
slow evaporation and co-solvent were applied. Such a high platinum recovery of the improved
formulations warrants their further characterizations.

Table 3.1
Composition and Platinum Recovery of Miriplatin-Loaded SLNs (90% TM or TP/10% PEPEG2000 +20% Miriplatin) Prepared by Different Preparation Procedures
SLN Compositions
Preparation methods
Platinum recovery (%)
+ drug input (%)
90% TM/10% PEG + 20% Miri

Chloroform dripping

9.02

90% TP/10% PEG + 20% Miri

Chloroform dripping

9.57

90% TM/10% PEG + 20% Miri

Chloroform injection

3.60

90% TP/10% PEG + 20% Miri

Chloroform injection

12.10

90% TM/10% PEG + 20% Miri

Chloroform evaporation

22.40

90% TP/10% PEG + 20% Miri

Chloroform evaporation

24.90

90% TM/10% PEG + 20% Miri

Co-solvent evaporation

20.00

90% TP/10% PEG + 20% Miri

Co-solvent evaporation

31.50

90% TM/10% PEG + 20% Miri

Chloroform slow evaporation

21.20

90% TP/10% PEG + 20% Miri

Chloroform slow evaporation

29.60

90% TM/10% PEG + 20% Miri

Co-solvent slow evaporation

87.80

90% TP/10% PEG + 20% Miri

Co-solvent slow evaporation

80.10

(TM: trimyristin, TP: tripalmitin, Miri: miriplatin, PEG: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt))
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Nonetheless, the platinum recovery quantified by ICP-OES cannot be simply taken as the
encapsulation efficiency of the nano formulations because the ICP traces the platinum element
regardless of its form. Due to its extremely low water solubility, we can reasonably assume that
free, intact miriplatin does not substantially partition into the bulk aqueous phase. However,
miriplatin may degrade (losing myristate chains) to convert its platinum into water-soluble
form(s) after long exposure to water. In this way, other forms of platinum (miriplatin
degradation products) could still be detected by ICP so that the actual encapsulation efficiency
may be lower than the platinum recovery. Therefore, the separation and quantification of
different forms of platinum are needed to more precisely assess the encapsulation efficiency.
Possible techniques in this regard include chloroform extraction and 195Pt-NMR [119, 120].
Moreover, storage procedures such as lyophilization and spray-drying are also needed to be
considered in order to reduce the time that miriplatin exposed to aqueous solution.
3.3.4.2 Platinum recovery of miriplatin-loaded nano formulations prepared by cosolvent slow evaporation. The composition and platinum recovery of miriplatin-loaded SLNs
and micelles that were prepared by the co-solvent slow evaporation method are shown in Table
3.2 and Table 3.3. All nano formulations were digested by 70% nitric acid at 90 ℃ for 90 min.
The platinum recovery of all such nano formulations were 70 % or higher. There was no
significant difference in platinum among different compositions. Adding cholesterol or another
anticancer drug Paclitaxel did not influence the platinum drug recovery, either. The
reproducibility could be improved by controlling the temperature increase more consistently for
each batch.
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Table 3.2
Composition and Platinum Recovery of Selected SLN Formulations Prepared by Co-Solvent
Slow Evaporation Method
Platinum
SLNs Compositions
Drug input (%)
recovery (%)
90% TM/10% PE-PEG2000

20% miriplatin

76.20

90% TP/10% PE-PEG2000

20% miriplatin

86.30

90% TM/10% PE-PEG2000

20% miriplatin + 10% PTX

83.20

90% TP/10% PE-PEG2000

20% miriplatin + 10% PTX

74.40

80% TM/10% Chol/10% PE-PEG2000

20% miriplatin

69.50

80% TP/10% Chol 10%/PE-PEG2000

20% miriplatin

81.40

(TM: trimyristin, TP: tripalmitin, Miri: miriplatin, PEG: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt), Chol:
cholesterol, PTX: paclitaxel)

Table 3.3
Composition and Platinum Drug Recovery of Selected Micelle Formulations Prepared by CoSolvent Slow Evaporation Method
Micelles Compositions
Drug input (%)
Platinum recovery (%)
100% PE-PEG2000

20% miriplatin

80.80

100% PE-PEG2000

20% miriplatin + 10% PTX

77.70

(TM: trimyristin, TP: tripalmitin, Miri: miriplatin, PEG: 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt), Chol:
cholesterol, PTX: paclitaxel)

3.3.5 Morphology of Miriplatin-Loaded Nano Formulations
Miriplatin-loaded nano formulations prepared by co-solvent evaporation method were
then subjected to morphological studies by TEM imaging.
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3.3.5.1 Morphology of miriplatin-loaded micelles. As shown in Figures 3.8 and 3.9,
micelles loaded with miriplatin only or with miriplatin and paclitaxel showed as little white dots
under TEM. Both of them had size around 10 nm, which was consistent with the size data
measured by dynamic light scattering. There was no obvious morphological difference between
the two compositions of micelles. The shape of micelles could not be observed clearly under
TEM due to the extremely small particle size. Some papers have reported that micelles
consisting of phospholipids or phospholipids-PEG conjugate had similar spherical structures
[121, 122].

Figure 3.8. TEM images of miriplatin-loaded micelles (100% PE-PEG2000 + 20% miriplatin).
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Figure 3.9. TEM images of miriplatin/paclitaxel-loaded micelles (100% PE-PEG2000 + 20%
miriplatin + 10% paclitaxel).

3.3.5.2 Morphology of miriplatin-loaded SLNs.
3.3.5.2.1 TM versus TP. The TEM images of SLNs consisting of TM or TP and loaded
with miriplatin are shown in Figure 3.10 and Figure 3.11. SLN with TP showed the morphology
of round-shape spheroids, while SLN with TM showed a mixture of spherical and rod structures.
It was reported that the shape (aspect ratio, AR) of lipid molecule impacted the shape of their
nanoparticles [77, 123]. When the size of the lipid head group is similar to the lipid tail (with an
AR of ~1), the lipid molecules tend to form spheres while rods are formed when the lipid tail is
bigger than the lipid head group (with an AR >2) [123]. However, our SLNs which consisted of
TM (containing two C-14 chains) formed rod-shaped nanoparticles while SLNs which consisted
of TP (containing two C-16 chains) formed spherical nanoparticles. TP might better bridge
between the lipid tail of PE-PEG conjugate (containing two C-18 chains) and that of miriplatin
(containing C-14 chains) to mix all the three components to form the sphere. As to SLNs with
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TM, most of the component molecules had C-14 chains (TM and miriplatin) so they would tend
to phase separate to form rods. The shape of nanocarriers have a huge effect on their behavior in
vivo behavior, such as cellular uptake [76, 77, 123, 124]. Some researchers reported that sphereshaped nanoparticles are more efficiently internalized by cells compared to rod-shaped ones, but
some recent studies showed contradictory results[76, 77, 123, 125]. Other than shape, factors
such as size, surface chemistry and material composition also influence the permeation into cell
membranes[77, 78]. Hence, both spherical shape and rod-shape warrant further in vitro and in
vivo studies.

Figure 3.10. TEM images of miriplatin-loaded SLNs consisting of TP (90% TP/10% PEPEG2000 + 20% miriplatin).
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Figure 3.11. TEM images of miriplatin-loaded SLNs consisting of TM (90% TM/10% PEPEG2000 + 20% miriplatin).

Both TM-containing and TP-containing SLNs averaged around 100 nm in diameter,
which was consistent with the sizing data from Zetasizer. These TEM images also support that
the number-based size distribution analyzed from Malvern Zetasizer software could represent the
size of the majority of nanoparticles. They had size distribution from 50 to 150 nm, which was
consistent with the high PDI values in their dynamic light scattering studies, both indicating the
substantial heterogeneity of the formulations. Some smaller particles (observed as 20-30 nm)
might be formed by the instability and degradation from bigger particles. The ones having size
around 10 nm could be explained by the self-assembly of only PE-PEG2000 and the formation of
micelles (similar to Figure 3.8 and Figure 3.9).
3.3.5.2.2 Effect of loading multiple drugs. The TEM images of miriplatin/paclitaxel
loaded SLNs (TP) are shown in Figure 3.12. Such SLNs loaded with both miriplatin and
paclitaxel showed similar morphology to the SLNs (TP) loaded only with miriplatin, both having
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spherical shape and size around 100 nm. There was no significant difference in the
physiochemical properties (including sizes, platinum drug recovery and morphology) between
the SLNs loaded with a single drug and a combination of two drugs. The black dots observed in
the left figure might be platinum-related compounds (miriplatin or its degradation products),
which could scatter electrons to display as darker particles of heavy metal against the
background. Some studies on cisplatin-loaded liposomes and platinum-based nanoparticles have
showed similar results [126, 127]. However, the black dots could not be found in most other
TEM images, so there is another possible explanation that the dark dots were caused by
excessive staining agent (uranyl acetate). Compared to liposome formulations, the SLN
formulations consisting of solid lipids and PE-PEG2000 conjugate had much more lipophilic
structure so they were difficult to be penetrated by the staining agent. Therefore, miriplatin and
its degradation products may not be easily observed under TEM.

Figure 3.12. TEM images of miriplatin/paclitaxel loaded SLNs of TP (90% TP/10% PE-PEG2000
+ 20% miriplatin + 10% paclitaxel).
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3.3.5.2.3 Effect of cholesterol. The TEM images of miriplatin-loaded SLNs (TP)
containing cholesterol are shown in Figure 3.13. Compared to SLNs (TP) without cholesterol,
they showed milky and brighter spheres. The TEM images also showed wider size distribution
and a combination of various structures including spheroids, rods and irregular shape, indicating
higher heterogeneity of the formulation. Hence, cholesterol did not improve the stability or
homogeneity of the SLNs as we expected from their function as a common bilayer stabilizer
[107]. However, different percentages of cholesterol and other stabilizers such as cholesteryl
palmitate as mentioned in Chapter 2 may be included in the SLNs in future studies.

Figure 3.13. TEM images of miriplatin-loaded SLNs (TP) containing cholesterol (80% TP/10%
cholesterol/10% PE-PEG2000 + 20% miriplatin).
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3.4 Summary
HPLC and ICP-OES techniques were attempted to quantify miriplatin. Miriplatin was
characterized by ESI-MS, which confirmed its chemical structure. A quantification method for
miriplatin was established using ICP-OES, which showed good consistency in different
platinum-containing samples including platinum standard solutions, cisplatin and miriplatin.
Recovery in the quantification of different miriplatin-loaded nano formulations was promoted by
digestion with 70% nitric acid and heating. The co-solvent slow evaporation method to prepare
platinum nano formulations improved the platinum recovery prominently from 10% to 70%.
The advantages and disadvantages of different methods to prepare platinum nano formulations
are summarized in Table 3.4. Other techniques are still needed to quantify the encapsulation
efficiency of miriplatin-loaded formulations in the future.
Miriplatin-loaded nano formulations with different compositions were negatively stained
with uranyl acetate and then imaged by TEM, which showed the size and morphology of the
miriplatin-loaded nano formulations that were consistent with size and PDI data from dynamic
light scattering studies by the Malvern Zetasizer. In the TEM studies, micelles showed a
morphology of spherical dots at around 10 nm in diameter while SLNs showed both spherical
and rod structures with a size distribution from 50 to 150 nm.
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Table 3.4
Comparison of Different Preparation Methods
Preparation methods

Pros

Cons

Easy to prepare

Poor reproducibility
Hard to scale-up

Simple
Better homogeneity

Low drug recovery

Chloroform evaporation

Simple

Poor homogeneity

Co-solvent evaporation

Slightly higher drug recovery

Larger size
Poor homogeneity

Slow evaporation

Slightly higher drug recovery

Poor homogeneity
Control T manually

Significantly higher drug recovery

Poor homogeneity
Control T manually

Thin-film hydration
Chloroform dripping/injection

Co-solvent slow evaporation
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CHAPTER 4: EVALUATION OF ANTICANCER ACTIVITY OF MIRIPLATIN-LOADED
NANO FORMULATIONS AGAINST 3D MCS

4.1 Introduction
The application of nanotechnology to clinically established medicine has prompted the
design and development of various drug-loaded nanocarriers to treat cancer [128]. However,
only a few nano formulations have been successfully translated into medicine in clinic [129].
Although huge resources have been invested in cancer research and nanotechnology, the
approval rate of neither anticancer drugs nor nanomedicines is above 5% [129, 130]. One main
reason for such low rate of success is the gap between pre-clinical cell culture and animal models
of cancer and real life cancer diseases [129, 130]. The current main strategies of screening
anticancer drugs are to use two-dimensional (2D) cell models and animal models. However, in
the last decade, it has been recognized that models of 2D monolayer cells cannot precisely select
clinically successful anticancer drugs [131].
Although 2D cell culture models carry many advantages including simplicity, low-cost,
reproducibility and high-throughout, it cannot mimic many unique features of solid tumors.
Firstly, 2D cell cultures lack many of the cell-cell and cell-matrix interactions seen in the tumor
microenvironment. Secondly, traditional 2D cell culture models lack many of the solid tumors’
physiological barriers against anticancer agents, which is the main reason that drug molecules
cannot easily penetrate into solid tumors [132]. Thirdly, 2D cell cultures also lack the
heterogeneity in oxygen, metabolites and pH, which are usually present in solid tumors.
Therefore, 2D cell culture models often incorrectly predict the efficacy and toxicity of an
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anticancer drug candidate, which would finally cause the failure in its clinical validation and
approval [133, 134].
Three dimensional multicellular spheroids (3D MCS) were first established by Sutherland
et al in the 1970s [135]. 3D MCS contain many features of solid tumors that are missing in 2D
cell culture model [136]. As shown in Picture 4.1, the 2D cell cultures result in monolayer cells
expanding on a flat surface while 3D cell cultures cause cells to form three-dimensional
spheroids using an ECM material [133]. 3D MCS can retain the characteristics of solid tumors
in patients very well and can create substantial barriers for drugs to penetrate [129]. Spheroids
with a diameter larger than 400–500 µm usually formed a hollowed-heart structure consisting of
an exterior layer of reproducing cells (proliferating zone), a middle layer of quiescent zone and
an internal necrotic core [129, 133, 137]. The various stages of cells within the spheroid
structure are established due to the gradients of oxygen and nutrients levels [138, 139]. A
schematic diagram of the structure of 3D MCS with different zones and inside gradients is
shown in Picture 4.1. In addition, 3D MCS can be cultured in vitro for weeks for long term
research and can be developed into co-culture models with other cells to better mimic the cellcell interaction [129]. Thus, a 3D MCS model carrying these characteristics can serve as a better
in vitro model than 2D cell culture models to mimic the solid tumor microenvironment and to
better predict the clinical efficacy of anticancer drug candidates.

87

Figure 4.1. Schematic diagrams of the traditional two-dimensional monolayer cell culture (A)
and three-dimensional cell culture systems (B, C). Adapted from [133].

3D MCS models have been widely used in preclinical studies on drug-loaded nano
delivery systems. Torchilin’s Group detected increased BCL-2 expression in an ovarian 3D
MCS model and used it to study the accumulation and toxicity of doxorubicin-loaded PEG-PE
micelles and solid lipid nanoparticles (co-loaded with doxorubicin and alpha-tocopherol
succinate) to overcome drug resistance [140, 141]. 3D MCS were also used to investigate the
EPR effect [65], which serves as the main mechanism of tumor targeting by nanocarrier-based
drug delivery systems. The penetration and retention of nanocarriers were evaluated in 3D MCS
that could reflect the vascular structure in solid tumors. For example, N. Ho et al developed

88
MCS that contain both cancer cells and vasculature endothelial cells to evaluate the penetration
of Fe3O4 nanoparticles and found that such nanoparticles selectively targeted the MCS
containing the endothelial cells and inhibited their growth more effectively than free drugs [142].
Further, 3D MCS can be inoculated into animals to establish patient-derived xenograft (PDX)
models in vivo [143].
In this chapter, lung adenocarcinoma A549 and A549-iRFP cells were constructed into
3D MCS (Figure 4.2) and used to evaluate the anticancer activity of miriplatin-loaded nano
formulations.

Figure 4.2. Schematic diagrams of 3D MCS produced by seeding cells into 96-well microplate
plates with noncell adherent surfaces. Adapted from [144].

4.2 Materials and Methods
4.2.1 Cell Culture Maintenance
Human lung adenocarcinoma A549 cell line was purchased from ATCC (Manassas, VA),
Human lung adenocarcinoma A549-iRFP cell line (λex =690 nm, λem = 713 nm) was purchased
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from Imanis Life Sciences (Rochester, MN). Cell culture reagents, if not specified, were
purchased from Corning Life Science. All cells were maintained at 37℃ and 5% CO2. A549
cells were grown in Roswell Park Memorial Institute Medium (RPMI) cell culture media with
supplemented 10% Fetal bovine serum (Gemini Bio-Products, CA) and 1% penicillinstreptomycin. A549-iRFP cells were grown in Dulbecco’s Modification of Eagle’s Medium
(DMEM) cell culture media supplemented with 10% Fetal bovine serum (Gemini Bio-Products,
CA), 1% penicillin-streptomycin and 1 µg/ml puromycin (Alfa Aesar, US).
4.2.2 Fluorometric Characterization of A549-iRFP Monolayer Cells
A549-iRFP cells were seeded onto Falcon™ 96-Well Black/Clear flat-bottom
microplates (Corning Life Science, US) at 0, 100, 200, 500, 800, 1000, 2000, 5000, 8000 and
10000 cells/well. The fluorescent signal (λex=685 nm, λem=700 nm) was monitored by
Odyssey® Infrared Imaging 205 System (LI-COR® Biosciences, Lincoln, NE, USA) at the 700
nm channel. The cell viability was measured by UV absorbance at 490 nm on a Synergy HTX
microplate reader (BioTek, US) using the CellTiter 96® AQueous One Solution Cell
Proliferation Assay (Promega Corporation, WI, US).
4.2.3 3D MCS Formation
A549 and A549-iRFP cells were seeded onto 96-well ultra-low attachment spheroid
microplates (Corning Life Science, US) at 3000 cells/well in 100 µL/well of the aforementioned
growth medium that was supplemented with 0.3% collagen (Gibco, US). The microplates were
centrifuged at 7 ℃, 300 g for 7 minutes on an Eppendorf Centrifuge 5810R to facilitate the
aggregation. The cells were cultured for 48 hours and then supplemented with another 100
µL/well growth medium without collagen. Every two days thereafter, the medium was changed
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by replacing 100 µL of growth medium in each well with 100 µL fresh growth medium without
collagen to maintain a 200 µL total media volume. The morphology of 3D MCS were monitored
by a Keyence (US) BZ-X700 fluorescence microscope.
4.2.4 Cell Viability Assays for Miriplatin-Loaded Nano Formulations on 3D MCS
A549 and A5499-iRFP cells (3000 cells/well) within 15 passages were seeded into 96well ultra-low attachment spheroid microplates (Corning Life Science, US) to form 3D MCS
using the method described above. After 6-8 days when 3D MCS grew to ~500 µm in diameter,
they were treated with free chemotherapeutic agents (cisplatin, miriplatin, paclitaxel) and
miriplatin-loaded nano formulations at the same platinum/paclitaxel input concentrations in
complete medium. Cisplatin was dissolved into complete medium directly while miriplatin and
paclitaxel were dissolved into complete medium containing 1% DMSO.
After incubation for 3 days at 37 °C, 5% CO2, the growth medium in each well was
removed completely and replaced by 200 µL fresh growth medium. After incubation for 2 more
days, 100 µL of the growth medium in each well was replaced with 100 µL fresh growth
medium to maintain a 200 µL total media volume. After incubation for another 2 days (3-day
exposure plus 4-day growth = 7 days in total), 3D MCS of each treatment group were transferred
to an opaque-walled 96-well plate with 100 µL medium in each well. An equal volume (100 µL)
of CellTiter-Glo 3D Cell Viability Assay (Promega Corporation, WI, USA) was added to each
well. The plate was shaken for 5 minutes and incubated for an additional 25 minutes at room
temperature to stabilize the luminescent signal. The luminescence was then recorded by a
Synergy HTX microplate reader (BioTek, US). The 3D MCS that were treated only with the
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growth media were assayed following the same procedure and taken as 100% viability (0%
inhibition) reference. Samples were evaluated in quadruplicates.
The fluorescent signal (λex =685 nm, λem = 700 nm) of A549-iRFP 3D MCS was
monitored daily during the 7-day treatment by Odyssey® Infrared Imaging 205 System (LICOR® Biosciences, Lincoln, NE, USA) at the 700 nm channel. The fluorescent signal of the 3D
MCS that were treated only with the growth media were taken as the reference for 100%
viability (0% inhibition). Samples were evaluated in quadruplicates.
The cell growth inhibition by miriplatin-loaded nano formulations are calculated by the
formula below:
𝐶𝑒𝑙𝑙 𝐺𝑟𝑜𝑤𝑡ℎ 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) = 100% − 𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%)
4.3 Results and Discussion
4.3.1 Correlation of Fluorescent Signal in A549-iRFP Monolayer Cells with Cell Seeding
Density and Cell Viability
A strong linear relationship was found between iRFP fluorescent signal of A549-iRFP
monolayer cells and cell seeding density. A linear relationship was also found between such
fluorescent signal and the cell viability. As shown in Figure 4.3, the fluorescent signal increased
with the increase of cell seeding density (R2=0.9902) and with the cell viability (R2 = 0.9313) as
long as the seeding density was in the range of 1000 to 10000 cells/well. The fluorescent signal
of A549-iRFP cells at seeding density below 1000 cells/well was too low to be quantified
precisely. With this relationship, the trend of the cell growth can be monitored by the iRFP
fluorescent signal of A549-iRFP cells. Although this correlation cannot be used to quantify the
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cell viability as precisely as the 3D cell viability assay, it allows dynamic assessment of the MCS
viability over the course of long treatments (7 days). The dynamic monitoring of the iRFP
fluorescence can not only assess the rate of cancer cell killing by anticancer agents/drug-loaded
delivery systems, but also assess whether the cancer cells in MCS will relapse after long term
exposure. For future studies, the correlation between the fluorescent signal of iRFP and seeding
density/viability should also be validated in 3D MCS.
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Figure 4.3. Correlation of iRFP fluorescent signal in A549-iRFP monolayer cells with cell
seeding density (lower left) and with cell viability (lower right). (Mean ± S.D, N = 6).
4.3.2 Formation of 3D MCS
The 3D MCS of two lung cancer cell lines (A549 and A549-iRFP) were successfully
constructed at selected seeding density (3000 cells/well) with the help of centrifugation and
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collagen addition in the growth media. The resultant 3D MCS showed a round, tight structure in
the first 15 days (Figure 4.4). The edge of MCS was smooth and clear in the first 10 days but
became fuzzy and rough from Day 13. MCS grew into ~500 µm in diameter after 5 to 7 days.
As reported previously [129, 133, 137], spheroids with diameter larger than 400–500 µm
transformed into a hollowed-heart structure consisting of an exterior layer of reproducing cells
(proliferating zone), a middle layer of quiescent cells and a core of necrotic cells.

Day 5

Day 7

Day 9

Day 11

Day 13

Day 15

Figure 4.4. Morphology of A549-iRFP 3D MCS (3000 cells/well) after 5, 7, 9, 11, 13, 15 days
of culturing (scale bar=500 µm).

4.3.3 Comparison between Sensitivity of A549 and that of A549-iRFP 3D MCS to
Anticancer Drugs and Nano Formulations
In order to validate A549-iRFP MCS as an alternative in vitro lung cancer model of A549
MCS, both MCS were treated with the same anticancer agents (cisplatin/paclitaxel) and
miriplatin-loaded nano formulations for comparison. The two types of MCS (Figure 4.5)
showed similar fifty percent inhibitory concentrations (IC50) of cisplatin with no significant
difference (p>0.05). Figure 4.6 showed the cell viability of 3D MCS of the two cell lines against
different miriplatin-loaded formulations. There was no significant difference between two cell
lines in most treatment group (p>0.05, except the TP/co-solvent group, p=0.0197). Therefore,
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3D MCS of A549-iRFP showed similar sensitivity to anticancer agents to 3D MCS of A549 and
could serve as a valid lung cancer model to evaluate anticancer drugs and drug delivery systems.
The treatment procedure of this study was 3-day agent exposure plus 4-day agent-free
growth. The medium with the free drugs/drug formulations was removed completely after 3-day
exposure and replaced by fresh growth medium for the following 4-day growth. During the 7day treatment, the iRFP florescent signal of A549-iRFP was recorded and analyzed to calculate
the cell viability. Compared to the traditional 72-hour exposure treatment, the modified
treatment procedure added 4 more days of drug-free growth to use the fluorescent signal to test
whether the cancer cells would relapse after the drug exposure. This modification was designed
to mimic the clinical regimens, where patients rest for weeks between each round of exposure to
chemotherapy agents while the efficacy and toxicity of chemotherapy are continuously
monitored.
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Figure 4.5. Cell viability of A549 (blue) and A549-iRFP (red) 3D MCS after 3-day exposure to
cisplatin plus 4-day cisplatin-free growth (Mean ± S.D, N = 4).
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Figure 4.6. Cell viability of A549 (blue) and A549-iRFP (red) 3D MCS after 3-day exposure to
miriplatin-loaded formulations plus 4-day drug-free growth (Mean ± S.D, N = 4).

4.3.4 Comparison of Anticancer Activity of Miriplatin-Loaded Nano Formulations
Prepared by Different Methods
The cell viability of A549-iRFP 3D MCS by miriplatin-loaded nano formulations
prepared by different methods was shown in Figure 4.7. The platinum recovery of each
formulation was quantified by ICP-OES. In order to better corelate anticancer activity and
platinum recovery, cell viability was transferred into growth inhibition by the equation
mentioned in 4.2.4 and showed in Figure 4.8. There was a strong relationship between platinum
recovery of different formulations and their anticancer activity that is assessed by both 3D
viability assay and iRFP fluorescence. The higher the platinum recovery, the higher the
anticancer activity would be. Although the platinum recovery could not be taken directly as the
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encapsulation efficiency of nano formulations (as mentioned in Chapter 3), it could reflect the
amount of miriplatin or its degradation products in the nano formulation preparation. The
positive association between the anticancer activity against A549-iRFP 3D MCS and the
platinum recovery supported this assumption. Thus, both platinum drug recovery and biological
activity results strongly suggest that nano formulations prepared by the chloroform
dripping/injection methods lost majority of the input miriplatin during the preparation. Cosolvent and slow evaporation both improved the platinum recovery. When both co-solvent and
slow evaporation were implemented in the preparation, the resultant nano formulation showed
significantly enhanced platinum recovery (>80%) and substantial anticancer activity against 3D
MCS in vitro.
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Figure 4.7. Cell viability of A549-iRFP 3D MCS after 3-day exposure to miriplatin-loaded nano
formulation prepared by different methods at 400 M input platinum concentration and 4-day
platinum-free growth. The platinum recovery of each formulation (green) is also listed for
reference (Mean ± S.D, N = 4). The cell viability is quantified by the iRFP fluorescent signal
(red) and by the 3D cell viability assay (blue). (TM: SLNs consisting of 90% TM/10% PEPEG2000 + 20% miriplatin; TP: SLNs consisting of 90% TP/10% PE-PEG2000 + 20% miriplatin)
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Figure 4.8. Growth inhibition of A549-iRFP 3D MCS after 3-day exposure to miriplatin-loaded
nano formulation prepared by different methods at 400 M input platinum concentration and 4day platinum-free growth. The platinum recovery of each formulation (green) is also listed for
reference (Mean ± S.D, N = 4). The growth inhibition is defined as 100% minus cell viability
quantified by the iRFP fluorescent signal (red) and by the 3D cell viability assay (blue). (TM:
SLNs consisting of 90% TM/10% PE-PEG2000 + 20% miriplatin; TP: SLNs consisting of 90%
TP/10% PE-PEG2000 + 20% miriplatin)

4.3.5 Anticancer Activity of Selected Miriplatin-Loaded Nano Formulations
The cell viability of A549-iRFP 3D MCS by miriplatin-loaded nano formulations
prepared by co-solvent slow evaporation method at platinum input concentration of 400 µM is
shown in Figure 4.9. All miriplatin-loaded nano formulations including micelles and SLNs
showed substantial anticancer activity against A549-iRFP, which was comparable to cisplatin, a
first-line anticancer drug against lung cancer. The low cell viability of these formulations
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(<10%) was correlated to their high platinum recovery (>70%) as shown in Chapter 3. The 3D
MCS treated by free miriplatin suspension showed no substantial anticancer activity. This is
most probably caused by its extremely low solubility in aqueous phase. The lack of anticancer
activity by miriplatin itself also indicates that miriplatin did not transform into any other
platinum compound of substantial anticancer activity.
The miriplatin input concentration at 400 µM was much higher than the IC50 value
(19.04 µM) of cisplatin against A549-iRFP 3D MCS. The high concentration of miriplatin was
initially used to screen different preparation methods to accommodate those that might have low
encapsulation efficiency or low anticancer activity. Although all the miriplatin-loaded nano
formulations prepared by co-solvent and slow evaporation showed extremely low cell viability
below 10%, it should not be concluded that their anticancer activities are all as good as cisplatin
because of their high input platinum concentration. In order to more thoroughly evaluate their
efficacy against lung cancer model A549-iRFP 3D MCS, cell viability should be assayed at
incremental concentration in comparison with cisplatin in the future. The slight difference of
cell viability between different formulations should not be considered as sufficient evidence that
which one was better than another for the same reason. The effect of combination therapy
(miriplatin and paclitaxel) and cholesterol on anticancer activity also need to be studied by such
dose response experiment.
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Figure 4.9. Cell viability of A549-iRFP 3D MCS after 3-day exposure to miriplatin-loaded nano
formulations prepared by the co-solvent slow evaporation method and 4-day drug-free growth
(Mean ± S.D, N = 4). The cell viability was quantified by iRFP fluorescence (red) and by 3D
cell viability assay (blue). (Miri: miriplatin, PTX: paclitaxel, Chol: cholesterol)

The daily dynamic change of iRFP fluorescent signal of A549-iRFP 3D MCS that have
been exposed to miriplatin-loaded nano formulations prepared by co-solvent slow evaporation
method is shown in Figure 4.10. The drastically higher fluorescent signal in the first three days
could be explained by the excess suspended nano formulation, which might give arteficial
signals by light scattering. After three-day exposure and change of growth medium, the
fluorescent signals of all the nano formulation groups were comparable to the fluorescent signals
of 3D MCS that had been treated with cisplatin. During the following four-day growth, both the
fluorescent signals of formulation groups and the cisplatin group stayed low without noticeable
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changes indicating that the three-day exposure was enough for extensive killing and that the
cancer cells did not relapse 4 days after the clearance of the anticancer agents.
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Figure 4.10. The dynamic change of iRFP fluorescent signal of A549-iRFP 3D MCS after 3-day
exposure to miriplatin-loaded nano formulations prepared by co-solvent slow evaporation and 4day drug-free growth (Mean ± S.D, N = 4). (Miri: miriplatin, PTX: paclitaxel, Chol: cholesterol)

4.4 Summary
A 3D MCS model of A549-iRFP was successfully established for in vitro evaluation of
activity against NSCLC. The viability of A549-iRFP 3D MCS after exposure to cisplatin or
nano formulations was similar to A549 3D MCS. The anticancer activity of miriplatin-loaded
formulations against 3D MCS was positively associated with the platinum recovery as quantified
by ICP-OES. The miriplatin-loaded nano formulations that had been prepared by the co-solvent
slow evaporation method showed substantial anticancer activity against A549 and A549-iRFP
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3D MCS, which was comparable to cisplatin. Such encouraging results warrant further studies
on miriplatin-loaded nano formulations in the future, such as dose-dependent viability of MCS
growth.
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CHAPTER 5: SUMMARY AND FUTURE WORK

Lung cancer claims the highest mortality and the second most new cases in the US.
Approximately 40% of newly diagnosed lung cancer patients are in the advanced stage IV, for
which platinum-based chemotherapy, individually or in combination with surgery or
radiotherapy, is the first-line treatment. After the clinical use of the first platinum drug, cisplatin,
many more platinum complexes have been investigated to overcome its drawbacks including
severe side effects and induction of drug resistance.
Several characteristics of solid tumors in lung cancer constitute a physiochemical barrier
to the deep penetration of chemotherapy agents. Nanocarriers provide a promising platform to
overcome the physiochemical barrier and to reduce the systemic toxicity of anticancer
chemotherapy. In this study, miriplatin, an exceptionally lipophilic platinum drug was
formulated with various lipid-based nanocarriers including micelles and solid lipid nanoparticles
(SLNs). The objective of this thesis project was to develop and evaluate miriplatin-loaded nano
formulations against lung cancer.
Miriplatin-loaded formulations were successfully prepared by different methods,
including one small, lab-scale method (thin film hydration) and several scale-up methods
(chloroform dripping, chloroform injection, chloroform evaporation, co-solvent evaporation,
chloroform slow evaporation and co-solvent slow evaporation). The size of the resultant nano
formulations was characterized by dynamic light scattering (DLS) and presented using numberweighted distribution. Different compositions of the nano formulations have been investigated.
Higher percentage of the pegylated lipid PE-PEG2000 in the composition resulted in smaller sizes.
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Among the two types of nano formulations under this study, micelles were much smaller (~10
nm in diameter) and more homogeneous (PDI < 0.3), while SLNs were bigger (~ 100 nm in
diameter) but had a more heterogeneous size distribution (PDI ~0.8).
HPLC and ICP-OES techniques were attempted to quantify miriplatin. Miriplatin was
characterized by ESI-MS, which confirmed its chemical structure. Quantification using HPLC
was attempted but then abandoned because of the low solubility and stability of miriplatin in
common mobile phases (water, methanol, ethanol and acetonitrile). Instead, a quantification
method for miriplatin was established using ICP-OES, which showed good consistency in
different platinum-containing samples including platinum standard solutions, cisplatin and
miriplatin. Platinum recovery in the quantification of different miriplatin-loaded nano
formulations was promoted by digestion with 70% nitric acid and heating at 90 ℃ for 90 min.
The solvent evaporation method to prepare miriplatin-loaded formulations improved the
platinum recovery prominently from 10% to 75% by adding co-solvent and by slow evaporation.
Thus, co-solvent slow evaporation has been established as a pharmaceutically viable scale-up
method to prepare nano formulations of miriplatin.
Miriplatin-loaded nano formulations of different compositions were negatively stained
with uranyl acetate and then imaged by TEM. The size and morphology of the miriplatin-loaded
nano formulations observed from TEM images were consistent with the size and PDI data from
DLS studies by the Malvern Zetasizer. In the TEM studies, micelles showed a morphology of
spherical dots at around 10 nm in diameter while SLNs showed both spherical and rod structures
with a size distribution from 50 to 150 nm.
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A 3D MCS model of A549-iRFP was successfully established for in vitro evaluation of
anticancer activity against lung cancer. A549-iRFP cells were engineered from the common
lung cancer cell line A549 to stably express the near infrared fluorescent protein (iRFP). A
strong linear relationship was found between iRFP fluorescent signal and cell viability. The cell
viability of A549-iRFP 3D MCS after exposure to cisplatin or nano formulations was similar to
A549 3D MCS. The anticancer activity of miriplatin-loaded formulations against 3D MCS was
positively associated with the platinum recovery by ICP-OES. The miriplatin-loaded nano
formulations that had been prepared by the co-solvent slow evaporation method showed
substantial anticancer activity against both A549 and A549-iRFP 3D MCS, which was
comparable to cisplatin. The growth of A549-iRFP 3D MCS after various treatment was
monitored by the iRFP fluorescent signal. Three-day exposure to miriplatin-loaded nano
formulations was enough for extensive killing and the cancer cells did not relapse during the
following 4 days of further culturing in drug-free media.
Future work for further development of miriplatin-loaded nano formulations would
include optimization of the lipid compositions. For examples, phospholipids and triglycerides
with different lengths of hydrocarbon chains can be tested as potential lipid components to
balance between stability and drug release; stabilizers such as cholesterol myristate can be added
into the lipid composition to improve the stability and homogeneity of nano formulations; the
surface of the nanocarriers can be modified with active targeting ligands to increase the drug
accumulation at the lung tumor site.
For future applications in industry, the scale-up method (co-solvent slow evaporation
method) also needs improvement to reduce batch-to-batch variance. The temperature increase
and the stirring speed can be better controlled by instrumental programming rather than manual
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operation. If needed, the key factors (such as solvent ratio, stirring speed and heating duration)
can be further investigated by design of experiments (DoE) to find their effects on the nano
formulations’ physiochemical properties. Moreover, storage procedures such as lyophilization
and spray-drying also need to be considered in order to reduce the degradation of the miriplatin
formulations in aqueous media.
In order to quantify the encapsulation efficiency of miriplatin-loaded nano formulations
for better dosage control in further in vitro and in vivo studies, different forms of platinum need
to be quantified. Possible techniques include chloroform extraction and 195Pt-NMR. In addition,
selected miriplatin-loaded formulations showed substantial anticancer activity against A549iRFP 3D MCS but at a high platinum dosage (400 µM). The dose-dependent inhibition of 3D
MCS growth by the miriplatin formulations need to be studied before further animal studies.
In conclusion, co-solvent slow evaporation has been established as a pharmaceutically
viable scale-up method to prepare miriplatin-loaded formulations that carry smaller size, low
PDI and high platinum recovery. A quantification method for miriplatin using ICP has been
established. Selected miriplatin-loaded formulations prepared by co-solvent slow evaporation
method showed substantial anticancer activities against A549 and A549-iRFP 3D MCS, which
were comparable to cisplatin, a first-line anticancer drug against lung cancer.
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